NZ746586B2 - Pyridinyl derivatives, pharmaceutical compositions and uses thereof as aoc3 inhibitors - Google Patents

Abstract

The invention relates to new pyridinyl and pyrimidinyl derivatives of the formula (I) wherein R1 and A are as defined in the description and claims, to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them. The invention is used as AOC3 inhibitors selective over AOC1 for the treatment of inflammatory disorders including diabetic retinopathy. ibitors selective over AOC1 for the treatment of inflammatory disorders including diabetic retinopathy.

Description

(12) d patent specificaon (19) NZ (11) 746586 (13) B2 (47) Publicaon date: 2021.12.24 (54) PYRIDINYL DERIVATIVES, PHARMACEUTICAL ITIONS AND USES THEREOF AS AOC3 INHIBITORS (51) Internaonal Patent Classificaon(s): C07D 401/14 C07D 405/14 C07D 413/14 C07D 401/04 C07D 417/14 A61K 31/506 A61P 1/16 A61P 29/00 (22) Filing date: (73) Owner(s): 2017.05.08 Boehringer Ingelheim International GmbH (23) Complete specificaon filing date: (74) Contact: 2017.05.08 Spruson & Ferguson Pty Ltd (30) Internaonal Priority Data: (72) or(s): EP 16169356.9 5.12 PETERS, Stefan BLUM, Andreas (86) Internaonal Applicaon No.: GODBOUT, Cédrickx HEHN, Joerg, P. (87) Internaonal Publicaon : WO/2017/194453 (57) Abstract: The invenon relates to new pyridinyl and pyrimidinyl derivaves of the formula (I) wherein R1 and A are as defined in the descripon and claims, to their use as medicaments, to s for their therapeuc use and to pharmaceucal composions containing them. The invenon is used as AOC3 inhibitors selecve over AOC1 for the treatment of inflammatory disorders including diabec renopathy. 746586 B2 NYL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF AS AOC3 INHIBITORS Field of the invention This ion relates to new compounds, in particular pyridinyl derivatives, to ses for ing such compounds, to their use as inhibitors of AOC3, to methods for their therapeutic use, in particular in diseases and conditions mediated by the inhibition of AOC3, and to pharmaceutical compositions sing them.

Background of the invention The enzymatic activity of AOC3 (amine oxidase, copper containing 3; vascular adhesion protein 1) has been described y in 1967 as a monoamine oxidase activity in the plasma of chronic liver disease patients (Gressner, A. M. et a|., 1982, J.

Clin. Chem. Clin. Biochem. 20: 509-514; McEwen, C. M., Jr. et a|.,1967, J. Lab Clin.

Med. 70: 36-47). AOC3 has two closely homologous genes in the human genome: AOC1 which corresponds to a diamine oxidase (Chassande, O. et a|., 1994, J. Biol.

Chem. 269: 14484-14489) and AOC2, a SSAO with a specific expression in the retina (lmamura, Y. et a|., 1997, Genomics 40: 277-283). AOC4 is a sequence that does not lead to a functional gene product in humans due to an internal stop-codon (Schwelberger, H. G., 2007, J. Neural Transm. 114: 757-762).

The enzyme contains an oxidized 2,4,5-trihydroxy-phenylalaninequinone (TPQ) and a copper ion in the active side. This characteristic catalytic center classifies the semi- carbazide-sensitive amine oxidase (SSAO, copper-containing amine:oxygen oxido- reductase (deaminating)): The type II membrane protein belongs to the family of copper containing amine oxidases together with several other diamine and the lysyl oxidases. r the later s can be distinguished from AOC3 in their preference for diamines and the low sensitivity towards semicarbazide inhibition (Dunkel, P. et a|., 2008, Curr. Med. Chem. 15: 1827-1839). On the other hand, monoamine es contain the flavin adenine dinucleotide (FAD) cofactor in their reactive center like monoamine e A (MAO-A) and ine oxidase B (MAO-B) and follow therefore a different reaction scheme.

AOC3 catalyzes a two-step reaction mechanism for the oxidative deamination of primary aliphatic and aromatic . In a first reaction the primary amine forms a Schiff—base with the TPQ aldehyde. This nt bond is hydrolyzed, releasing the 2017/060890 aldehyde product and a substituted TPQ residue in the active site. In the presence of oxygen, TPQ is oxidized under the formation of ammonia and peroxide with the help of the copper ion (Mure, M. et a|., 2002, Biochemistry 41: 9269-9278). Several ates of AOC3 have been described, like the physiological amines methylamine, dopamine, or aminoacetone, whose products of oxidation have been associated to vascular pathologies (Yu, P. H. et al.,1993, Diabetes 42: 594-603). Synthetic amines have been optimized for their turnover by AOC3 like benzylamine derivates a, F. et a|., 2006, J. Med. Chem. 49: 6197-6208), C-Naphthalenmethylamine (Marti, L. et a|., 2004, J. Med. Chem. 47: 4865-4874) or luciferin tes (Valley, M.

P. et al., 2006, Anal. Biochem. 359: 238-246). The later substrate can be used for the ive detection of AOC3 activity in plasma, tissue or for biochemical characterization of the enzyme.

Under pathophysiological conditions of high AOC3 activity the aldehyde products are highly reactive, leading to advanced glycosylation end products (Mathys, K. C. et a|., 2002, Biochem. Biophys. Res. Commun. 297: 863-869) which are regarded as markers and drivers of diabetes associated matory mechanisms. rmore, the byproduct hydrogen peroxide is sensed by the tissue as a messenger of inflammation. This on t is able to activate the endothelium and is fostering the activation of leukocytes.

The binding and modification of Siglec-10 as a membrane bound substrate provides a mechanistic understanding of how the enzymatic reaction could trigger the leukocyte transmigration through activated endothelia. The binding of Siglec—10 to AOC3 was shown in l adhesion assays and led to increased hydrogen de production (Kivi, E. et a|., 2009, Blood 114: 5385-5392). Binding of ted leukocytes to the dimeric, ellular AOC3 via the Siglec-10 generates a transient association to the activated endothelium. Therefore, the rolling velocity of leukocytes is reduced, which increases the transmigration of leukocytes into the interstitium of inflamed tissues. Further, a conserved tif on the surface of AOC3 argues for its adhesive role: The deletion of this sequence reduced leukocyte recruitment (Salmi, M. et a|., 2000, Circ. Res. 86: 1245-1251), probably via a lack of integrin B1 binding activity (Aspinall, A. I. et a|., 2010, Hepatology 51: 2030-2039).

This finding correlates to the phenotype of AOC3 knock out mice, which exert a reduced leukocyte and lymphocyte transmigration ty (Stolen, C. M. et al., 2005, Immunity. 22: 105-115) into lymphoid organs and adipose tissue (Bour, S. et al., 2009, Am. J. Pathol. 174: 1075-1083).

AOC3 activity can be found in most tissues and is mainly expressed in endothelial cells, smooth muscle cells and adipocytes (Boomsma, F. et al.,2000, Comp Biochem.

Physiol C. Toxicol. Pharmacol. 126: 69-78; ivan, J. et al.,2004, Neurotoxicology : 303-315). In humans, in contrast to mice, AOC3 ty is constitutive in the liver sinusoideal endothelial cells , G. et al., 1996, Gastroenterology 110: 8) and mRNA expression is further upregulated under inflammatory conditions in this tissue (Lalor, P. F. et al., 2002, lmmunol. Cell Biol. 80: 52-64); Bonder, C. S. et al., 2005, Immunity. 23: 153-163). AOC3 not only exists as a membrane n, but can also be found as soluble plasma activity probably due to a metalloprotease mediated shedding process (Abella, A. et al., 2004, Diabetologia 47: 429-438); Boomsma, F. et al., 2005, ologia 48: 1002-1007; Stolen, C. M. et al., 2004, Circ. Res. 95: 50- 57)). Elevated levels of soluble AOC3 have been observed in diabetes (Li, H. Y. et al., 2009, Clin. Chim. Acta 404: 149-153), obesity (Meszaros, Z. et al., 1999, Metabolism 48: 113-117; Weiss, H. G. et al., 2003, lism 52: 688-692), congestive heart failure (Boomsma, F. et al., 1997, Cardiovasc. Res. 33: 387-391), age renal disease (Kurkijarvi, R. et al., 2001, Eur. J. lmmunol. 31: 2876-2884) and inflammatory liver disease (Kurkijarvi, R. et al., 1998, J. l. 161: 1549- 1557). For the latter, levels of AOC3 plasma activity have been correlated to liver fibrosis and serve as a predictor in patients with NAFLD (Weston, C. J. et al., 2011, J.

Neural Transm. 118: 1055-1064). After lantation of cirrhotic livers, high AOC3 plasma levels returned to normal values, which argues for the liver as the major source of plasma AOC3 activity under this pathological condition (Boomsma, F. et al., 2003, Biochim. Biophys. Acta 1647: 48—54).

The role of AOC3 in the activation of inflammation via peroxide generation and the recruitment of leukocytes to activated elium makes it an attractive target for the treatment of inflammatory components in l diseases. Therefore a variety of small molecular nds and antibodies have been tested in different disease animal models. Amongst those, the inhibition of AOC3 showed beneficial effects in the models of melanoma and lymphoma cancer (Marttila-lchihara, F. et al., 2010, J.

Immunol. 184: 3164-3173), acute and chronic joint (Tabi, T. et al., 2013, J. Neural Transm. 120: 963-967) or lung (Foot, J. S. et al., 2013, J. Pharmacol. Exp. Ther. 347: 365-374) inflammation, diabetic macular edema (lnoue, T. et al., 2013,Bioorg. Med.

Chem. 21: 1219-1233), kidney fibrosis (Wong, M. et al., 2014, Am. J. Physiol Renal Physiol 307: F908-F916), liver aft rejection (Martelius, T. et al., 2004, Am. J.

Pathol. 165: 1993-2001) and non-alcoholic liver disease.

The development of a ive, potent and well tolerated AOC3 inhibitor would therefore be cial for the treatment of the tive human diseases.

AOC3 inhibitors are known in the art, for example, the compounds disclosed in EP 2 695 881 corresponding to . The pyridinyl derivatives of the present invention may e several ages, such as ed potency, reduced plasma protein binding, improved CYP hrome P450) enzyme profile and high metabolic stability, high chemical stability, improved tissue distribution, improved side effect profile and/or tolerability and in consequence low toxicity, reduced risk to cause adverse events or undesirable side effects, and enhanced solubility. The pyridinyl derivatives of the present invention exhibit increased selectivity towards AOC1. AOC1 expression and enzymatic activity is mainly found in the gut, placenta and kidney. The enzyme catalyzes the oxidation of primary amines derived from nutrition and protects the individuum from cardiometabolic effects of histamine, putrescine, tryptamine and cadaverine. Inhibition of AOC1 can lead to impaired tolerance to ingested histamine, resulting in increased plasma and tissue histamine-levels which can cause adverse events or undesirable side s like decreased l re and compensation by increased heart-rate, tachycardia, headache, flush, urticaria, pruritus, bronchospasm and cardiac arrest (Maintz L. and Novak N. 2007. Am. J. Clin. Nutr. 85:1185-96). The consequence of AOC1 inhibition in combination with histamine intake has been demonstrated in ments with pigs: After the application of the AOC1-inhibitor aminoguanidine (100 mg/kg) and gavage of histamine (2 mg/kg) s experienced increased ine blood levels accompanied with a drop of blood pressure, increased heart rate, flushing, vomiting and death (3 out of 15 animals) (Sattler J. 1988. Agents and Actions, 23: 361-365) under the experimental conditions. Histamine intolerance in humans was associated _ 5 _ to mutations in the promoter region of A001, leading to reduced mRNA expression and plasma AOC1 activity (Maintz et al. 2011. Allergy 66: 893—902).

Aim of the present invention The aim of the present invention is to e new compounds, in particular new pyridinyl derivatives, which are active with regard to AOC3.

A further aim of the present invention is to provide new compounds, in ular new pyridinyl derivatives, which have an inhibitory effect on AOC3 in vitro and/or in vivo and possess suitable pharmacological and pharmacokinetic properties to use them as medicaments.

A further aim of the present invention is to provide effective AOC3 inhibitors, in particular for the ent of various diseases, for example of NASH (non-alcoholic steatohepatitis), pulmonary fibrosis, retinopathy and nephropathy.

Another aim of the present invention is to provide effective AOC3 inhibitors for the treatment of metabolic disorders such as NASH (non-alcoholic steatohepatitis), ary fibrosis, retinopathy and nephropathy.

A further aim of the present invention is to e methods for treating a disease or condition mediated by the inhibition of A003 in a t.

A further aim of the present invention is to e a ceutical composition sing at least one compound according to the invention.

A further aim of the present invention is to provide a combination of at least one compound according to the invention with one or more additional therapeutic agents.

A further aim of the present invention is to provide methods for the sis of the new compounds, in particular pyridinyl derivatives.

W0 2017/194453 _ 6 _ A further aim of the t invention is to provide ng and/or intermediate compounds suitable in methods for the synthesis of the new compounds.

Further aims of the present invention become apparent to the one skilled in the art by the description hereinbefore and in the following and by the examples.

Object of the Invention Within the scope of the present invention it has now surprisingly been found that the new compounds of general formula (I) as described hereinafter exhibit an inhibiting activity with regard to AOC3.

According to another aspect of the present invention it has been found that the new compounds of general formula (I) as described hereinafter exhibit an inhibiting activity with regard to AOC3.

In a first aspect the present invention es a compound of general formula \ O H NH A \ N 2 | T T 1 O NH R N (I), wherein A is selected from the group A-G1 consisting of: N and CH; R1 is selected from the group R1-G1 consisting of: C1-e-alkyl, 03cycloalkyl, heterocyclyl, -O-R2, -S-R2, -NH-R2 and -N(R2)2, n each R2 is independently selected from the group RZ-Gi consisting of C1_e-alkyl, ycloalkyl, cyclyl, -(C1_2-alkyl)-(Cg_6- cycloalkyl), -(C1alkyl)—heterocyclyl, -alkyl)-aryl, -(C1_2-alkyl)- heteroaryl and —(C1alkyl)-CECH; wherein each heterocyclyl of R1 and R2 is a 4- to 7-membered saturated carbocyclic group, in which 1 or 2 ieties are independently of each other replaced by an atom or group selected from NH, O, S, -S(=O)-, -S(=O)2- or—C(=O)—; and wherein each aryl is selected from the group consisting of phenyl and naphthyl; and wherein each heteroaryl is a 5- or 6—membered heteroaromatic ring which contains 1, 2 or 3 heteroatoms independently selected from =N-, -NH-, -O- and —S—, wherein in aromatic groups containing a —CH=N- unit, this group is optionally replaced by — NH-C(=O)—; and wherein each alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl group of R1 and R2 is optionally independently substituted with one or more F, Cl, CN, OH, 01alkyl, -O-(C1_3-alkyl), —C(=O)—(C1alkyl) and —(Cgcycloalkyl); wherein each of the above-mentioned alkyl and —O-alkyl groups may be linear or branched and are optionally substituted by one or more F; a tautomer or isomers thereof, or a salt thereof, or a e or hydrate thereof.

In a further aspect the t ion relates to processes for preparing a compound of l formula (I) and to new intermediate compounds in these ses.

A further aspect of the invention relates to a salt of the compounds of general formula (I) according to this invention, in particular to a pharmaceutically acceptable salt thereof.

In a further aspect this invention s to a pharmaceutical composition, sing one or more compounds of general formula (I) or one or more pharmaceutically acceptable salts thereof according to the invention, optionally together with one or more inert carriers and/or diluents.

In a further aspect this invention relates to a method for treating diseases or conditions which are mediated by inhibiting the ty of A003 in a patient in need thereof characterized in that a compound of general formula (I) or a ceutically acceptable salt thereof is stered to the t.

According to another aspect of the invention, there is provided a method for treating NASH (non-alcoholic steatohepatitis), pulmonary fibrosis, retinopathy or nephropathy in a patient in need thereof characterized in that a compound of general formula (I) or a pharmaceutically acceptable salt thereof is administered to the patient.

According to another aspect of the invention, there is provided the use of a compound of the general formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for a therapeutic method as described above or hereinafter.

According to r aspect of the invention, there is provided a compound of the general formula (I) or a pharmaceutically acceptable salt thereof for use in a therapeutic method as described above or hereinafter.

In a further aspect this invention relates to a method for treating a disease or condition mediated by the tion of A003 in a patient that includes the step of administering to the patient in need of such treatment a therapeutically effective amount of a compound of the general formula (I) or a pharmaceutically acceptable salt thereof in combination with a eutically effective amount of one or more additional therapeutic .

In a further aspect this invention relates to a use of a compound of the general formula (I) or a ceutically acceptable salt thereof in combination with one or more additional therapeutic agents for the treatment or prevention of diseases or conditions which are mediated by the inhibition of AOC3.

In a further aspect this invention relates to a pharmaceutical composition which comprises a compound according to general formula (I) or a pharmaceutically acceptable salt thereof and one or more additional therapeutic agents, optionally together with one or more inert carriers and/or diluents.

Other aspects of the invention become apparent to the one d in the art from the specification and the experimental part as described hereinbefore and hereinafter.

Detailed ption Unless otherwise stated, the groups, residues, and substituents, ularly A, R1 and R2, are defined as above and hereinafter. If residues, substituents or groups occur several times in a nd, as for example R2, they may have the same or different meanings. Some preferred meanings of individual groups and substituents of the nds according to the invention will be given hereinafter. Any and each of these definitions may be combined with each other.

A-G1: The group A is preferably selected from the group A-G1 as defined above.

A-G2: In another embodiment the group A is ed from the group A-G2 consisting of N.

A-G3: In another embodiment the group A is selected from the group A-G3 consisting of R1-G1: The group R1 is preferably selected from the group R1-G1 as defined above.

R1-G2: In one embodiment the group R1 is selected from the group R1-G2 consisting of: 01alkyl, Cgcycloalkyl, heterocyclyl, -O-R2, -S-R2, -NH-R2 and -N(R2)2; wherein each heterocyclyl is a 4- to 6—membered saturated carbocyclic group, in which 1 or 2 CHg-moieties are replaced by a heteroatom selected from NH, O or S; and n each alkyl, cycloalkyl or heterocyclyl group is optionally independently tuted with 1 to 5 F and / or 1 to 3 substituents independently selected from the group consisting of Cl, CN, OH, 01alkyl, -O-(C1alkyl), —C(=O)—(C1_ 2-alkyl) and —C(=O)—(Cgcycloalkyl).

R1-G3: In another embodiment the group R1 is ed from the group R1-G3 consisting of: 01alkyl, 03cycloalkyl, heterocyclyl, -O-R2, -S-R2, -NH-R2 and 2; wherein each cyclyl is selected from the group consisting of azetidinyl, piperidinyl, piperazinyl, tetrahydrofuranyl, tetrahydropyranyl and morpholinyl; and wherein each alkyl, cycloalkyl or heterocyclyl group is optionally independently substituted with 1 to 3 F and / or one substituent selected from the group consisting of CN, OH, CH3, -O-CH3, —C(=O)—CH3 and —C(=O)—cyclopropyl.

R1-G4: In another embodiment the group R1 is ed from the group R1-G4 consisting of: C1alkyl, C3cycloalkyl, heterocyclyl, -O-R2, -NH-R2 and -N(R2)2; wherein each heterocyclyl is ed from the group consisting of azetidinyl, piperidinyl, tetrahydrofuranyl, ydropyranyl and morpholinyl; and wherein each alkyl, cycloalkyl or heterocyclyl group is optionally independently substituted with 1 to 3 F or one substituent selected from the group consisting of CN, OH, CH3, -O-CH3, —C(=O)—CH3 and —C(=O)—cyclopropyl.

R1-G5: In another embodiment the group R1 is selected from the group R1-G5 consisting of: cyclopropyl, cyclyl and -O-R2; wherein each heterocyclyl is selected from the group consisting of azetidinyl, piperidinyl, tetrahydrofuranyl, tetrahydropyranyl and linyl; and wherein each heterocyclyl group is optionally independently substituted with one substituent selected from the group consisting of F, CN, OH, CH3, -O-CH3.

R1-G6: In another embodiment the group R1 is ed from the group R1-G6 consisting of: a) CH3; b) —O-C1alkyl optionally substituted with 1-3 F or one —OCH3; c) —O-C2alkyl terminally tuted with —CECH; d) —S—CH3; e) cyclopropyl; f) —NH-(C1_3-alkyl) and —N(CH3)(C1_3-alkyl), wherein each alkyl group is optionally substituted with 1-3 F or one —OCH3; g) azetidinyl, tetrahydropyranyl and morpholinyl, each optionally substituted with —OCH3; h) tetrahydrofuranyloxy; i) —O-CH2—R3, wherein R3 is 03cycloalkyl optionally substiuted with 1 or 2 substituents independently selected from the group consisting of F and ON; ydropyranyl; piperidinyl optionally substituted with —C(=O)—CH3 or —C(=O)—cyclopropyl; isoxazolyl, thiazolyl or thiadiazolyl; j) —O-CH(CH3)-oxazolyl; k) —N(RN)-R4, wherein RN is H or CH3‘ and R4 is tetrahydrofuranyl, tetrahydropyranyl or —(CH2)—isoxazolyl.

R1-G7: In r embodiment the group R1 is selected from the group R1-G7 consisting of: F F F * a o Cu O CH \—CH */ \/\CH */ CH */ \XCH 3 3 3 3 3 ’ ’ ’ ’ ’ /CF3 */O\/\O/CH3 */O\/\// *4 ’ ’ & CCC N *—O \Afl\\ F \7<> *—o *— *—O F \ \ < // N \—<Njo —O W\ *—O S *—O *—O S L< j Lfs ‘ H3C N/O \N N; Lg\ WIN R2: R2-G1: The group R2 is preferably ed from the group RZ-G1 as defined above.

R2-G2: In one embodiment the group R2 is selected from the group RZ-GZ consisting of lkyl, Cgcycloalkyl, heterocyclyl, -alkyl)—(Cg_5-cycloalkyl), -(C1_2-alkyl)- heterocyclyl, -(C1_2-alkyl)-aryl, -(C1_2-alkyl)-heteroaryl and —(C1_2-alkyl)-CECH; wherein each heterocyclyl is a 4- to 6—membered saturated carbocyclic group, in which 1 or 2 CHg-moieties are replaced by a heteroatom selected from NH, O or S; and wherein each aryl is selected from the group consisting of phenyl and yl; and wherein each heteroaryl is a 5- or 6—membered heteroaromatic ring which contains 1, 2 or 3 heteroatoms independently selected from =N-, -NH-, -O- and —S—; and wherein each alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl group is optionally independently substituted with one or more F, Cl, CN, OH, 01alkyl, -O-(C1alkyl), —C(=O)—(C1alkyl) and —C(=O)—(Cgcycloalkyl).

R2-G3: In another embodiment the group R2 is selected from the group RZ-G3 consisting of 01alkyl, ycloalkyl, heterocyclyl, -(C1_2-alkyl)—(Cg_4-cycloalkyl), -alkyl)- heterocyclyl, -(C1_2-alkyl)-phenyl, -alkyl)-heteroaryl and —(C1_2-alkyl)-CECH; wherein each heterocyclyl is selected from the group consisting of azetidinyl, tetrahydrofuranyl, tetrahydrofuranyl and piperidinyl; and wherein each heteroaryl is selected from the group consisting of isoxazolyl, thiazolyl and azolyl; and wherein each alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl group is optionally independently tuted with one or more F, CN, OH, CH3, -OCH3, —CH3 and —C(=O)—cyclopropyl.

R2-G4: In another embodiment the group R2 is selected from the group RZ-G4 consisting of 01alkyl, -CH2—(Cgcycloalkyl), -CH2—heterocyclyl, -CH2—heteroaryl and —CH2—CH2— CECH; wherein each heterocyclyl is selected from the group consisting of tetrahydro- furanyl and piperidinyl; and wherein each heteroaryl is ed from the group consisting of isoxazolyl, thiazolyl and thiadiazolyl; and wherein each alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl group is optionally independently substituted with one or more F, CN, CH3, -OCH3, — C(=O)—CH3 and —C(=O)—cyclopropyl.

R2-G5: In another embodiment the group R2 is selected from the group RZ-G5 consisting of 01alkyl, -CH2—(Cgcycloalkyl), -CH2—heteroaryl and —CH2—CH2—CECH; 2017/060890 wherein each heteroaryl is selected from the group consisting of isoxazolyl, thiazolyl and thiadiazolyl; and wherein each alkyl, cycloalkyl, aryl or heteroaryl group is optionally independently substituted with one or more F, CN and -OCH3.

Examples of preferred subgeneric embodiments according to the present invention are set forth in the following table, wherein each substituent group of each embodiment is defined according to the definitions set forth above: No. A R1 R2 1 A-G1 R1-G1 RZ-Gf 2 A-G2 R1-G1 RZ-Gf 3 A-G1 R1-G1 RZ-GZ 4 A-G2 R1-G1 RZ-GZ A-G1 R1-G1 RZ-G3 6 A-G2 R1-G1 RZ-G3 7 A-G1 R1-G1 RZ-G4 8 A-G2 R1-G1 RZ-G4 9 A-G1 R1-G1 RZ-G5 1o A-G2 R1-G1 R2-G5 11 A-G1 R1-G2 RZ-Gf 12 A-G2 R1-G2 RZ-Gf 13 A-G1 R1-G2 RZ-GZ 14 A-G2 R1-G2 R1-G2 A-G1 R1-G2 RZ-G3 16 A-G2 R1-G2 RZ-G3 17 A-G1 R1-G2 RZ-G4 18 A-G2 R1-G2 RZ-G4 19 A-G1 R1-G2 R2-G5 A-G2 R1-G2 R2-G5 21 A-G1 R1-G3 RZ-G1 WO 94453 _ 16 _ No. A R1 R2 22 A-G2 R1-G3 RZ-G1 23 A-G1 R1-G3 RZ-GZ 24 A-G2 R1-G3 R2-G2 A-G1 R1-G3 RZ-G3 A-G2 R1-G3 RZ-G3 27 A-G1 R1-G3 RZ-G4 28 A-G2 R1-G3 RZ-G4 29 A-G1 R1-G3 RZ-G5 A-G2 R1-G3 RZ-G5 31 A-G1 R1-G4 RZ-G1 32 A-G2 R1-G4 RZ-G1 33 A-G1 R1-G4 R2-G2 34 A-G2 R1-G4 RZ-GZ A-G1 R1-G4 RZ-G3 A-G2 R1-G4 RZ-G3 37 A-G1 R1-G4 RZ-G4 38 A-G2 R1-G4 R2-G4 39 A-G1 R1-G4 RZ-G5 4o A-G2 R1-G4 R2-G5 41 A-G1 R1-G5 RZ-G1 42 A-G2 R1-G5 RZ-G1 43 A-G1 R1-G5 RZ-GZ 44 A-G2 R1-G5 RZ-GZ 45 A-G1 R1-G5 RZ-G3 45 A-G2 R1-G5 RZ-G3 47 A-G1 R1-G5 RZ-G4 48 A-G2 R1-G5 RZ-G4 49 A-G1 R1-G5 RZ-G5 50 A-G2 R1-G5 RZ-G5 51 A-G1 R1-G6 - 52 A-G2 R1-G6 - 53 A-G1 R1-G7 — No. A R1 R2 54 A-G2 R1-G7 - 55 A-G3 R1-G1 RZ-G1 55 A-G3 R1-G2 RZ-GZ 57 A-G3 R1-G3 RZ-GZ 58 A-G3 R1-G3 RZ-G3 59 A-G3 R1-G4 RZ-G3 50 A-G3 R1-G4 RZ-G4 51 A-G3 R1-G4 RZ-G5 52 A-G3 R1-G5 RZ-G4 53 A-G3 R1-G5 RZ-G5 54 A-G3 R1-G6 - 55 A-G3 R1-G7 — The following preferred embodiments of compounds of the formula (I) are described using c formulae (L1) to (l.2), wherein any tautomers and stereoisomers, solvates, hydrates and salts thereof, in particular the pharmaceutically acceptable salts thereof, are encompassed. l H o N N (H) H2 N \ \N WY 1A / 0 NH R N \N o H N (l.2) \ H2 1 0 NH R N wherein in of the above formulae (L1) to (l.2), the group R1 is as defined above.

A preferred embodiment of the present invention ns nds of formula wherein R1 is selected from the group consisting of cyclopropyl, heterocyclyl and -O-R2; wherein R2 is selected from the group consisting of C1-s-alkyl, -(C1_2-alkyl)-(Cg_ e-cycloalkyl), --(C1alkyl)-heteroaryl and —(C1_2-alkyl)-CECH; wherein each heterocyclyl is selected from the group consisting of azetidinyl, piperidinyl, tetrahydrofuranyl, tetrahydropyranyl and linyl; and wherein each cyclyl group is optionally ndently substituted with one substituent selected from the group consisting of F, CN, OH, CH3, -O-CH3; and wherein each heteroaryl is selected from the group consisting of isoxazolyl, thiazolyl and thiadiazolyl; and wherein each alkyl, cycloalkyl, heterocyclyl, or heteroaryl group is optionally independently tuted with one or more F, CN, CH3, - OCH3, —C(=O)—CH3 and —C(=O)—cyclopropyl; or a salt thereof, preferably a pharmaceutically able salt thereof.

Another preferred embodiment of the present ion concerns compounds of formula (l.1), wherein R1 is selected from the group consisting of cyclopropyl, heterocyclyl and -O-R2; wherein R2 is selected from the group consisting of 01alkyl, -CH2-(Cg cycloalkyl), -CH2—heteroaryl and —CH2—CH2—CECH; wherein each heteroaryl is selected from the group consisting of isoxazolyl, thiazolyl and thiadiazolyl; and wherein each alkyl, cycloalkyl, aryl or heteroaryl group is optionally ndently substituted with one or more F, CN and -OCH3. wherein each heterocyclyl is selected from the group consisting of azetidinyl, dinyl, tetrahydrofuranyl, ydropyranyl and morpholinyl; and wherein each heterocyclyl group is optionally ndently substituted with one substituent selected from the group consisting of F, CN, OH, CH3, -O-CH3; or a salt thereof, ably a pharmaceutically acceptable salt thereof.

Preferred compounds of the invention include: >—<’N \ / \ N_ N— W0 2017/194453 2017/060890 _</N \ / \ F O as H F O )—NH 0 )=NH N— N— O H )i—N o )—NH2 *WN F?mill/ N_ N— F H O )=NH and the salts thereof, preferably the pharmaceutically acceptable salts thereof.

Particularly preferred compounds, including their tautomers and stereoisomers, the salts thereof, or any solvates or hydrates thereof, are described in the experimental section hereinafter.

The nds according to the invention may be ed using methods of synthesis which are known to the one skilled in the art and described in the literature of organic synthesis. Preferably, the compounds are obtained analogously to the methods of preparation explained more fully hereinafter, in particular as described in the experimental section. 2017/060890 Terms and definitions Terms not specifically defined herein should be given the meanings that would be given to them by one of skill in the art in light of the disclosure and the t. As used in the specification, however, unless specified to the contrary, the following terms have the meaning indicated and the following conventions are adhered to.

The terms "compound(s) according to this invention", "compound(s) of formula (l)", "compound(s) of the invention" and the like denote the compounds of the formula (I) according to the present invention including their tautomers, isomers and es thereof and the salts thereof, in particular the pharmaceutically acceptable salts f, and the solvates and hydrates of such compounds, including the solvates and hydrates of such tautomers, stereoisomers and salts thereof.

The terms "treatment" and "treating" embraces both tative, i.e. prophylactic, or therapeutic, i.e. curative and/or palliative, treatment. Thus the terms "treatment" and ing" comprise therapeutic treatment of ts having already developed said condition, in particular in manifest form. Therapeutic treatment may be symptomatic treatment in order to relieve the symptoms of the specific indication or causal treatment in order to reverse or lly reverse the conditions of the indication or to stop or slow down progression of the disease. Thus the compositions and methods of the t invention may be used for instance as eutic treatment over a period of time as well as for chronic therapy. In addition the terms "treatment" and ing" comprise prophylactic treatment, Le. a treatment of patients at risk to p a condition mentioned hereinbefore, thus reducing said risk.

When this invention refers to patients requiring treatment, it relates primarily to treatment in mammals, in ular humans.

The term "therapeutically effective amount" means an amount of a compound of the present invention that (i) treats or prevents the particular disease or condition, (ii) attenuates, ameliorates, or eliminates one or more symptoms of the particular disease or condition, or (iii) prevents or delays the onset of one or more symptoms of the particular disease or condition described herein.

The terms "modulated" or "modulating", or "modulate(s)", as used herein, unless otherwise ted, refers to the inhibition of AOC3 with one or more compounds of the present ion.

The terms "mediated" or ting" or "mediate", as used , unless otherwise indicated, refers to the (i) treatment, including prevention the particular disease or condition, (ii) attenuation, amelioration, or elimination of one or more symptoms of the particular disease or condition, or (iii) prevention or delay of the onset of one or more symptoms of the particular disease or condition described herein.

The term "substituted" as used herein, means that any one or more hydrogens on the designated atom, radical or moiety is replaced with a selection from the indicated group, provided that the atom's normal valence is not exceeded, and that the substitution results in an acceptably stable compound.

In the groups, radicals, or moieties defined below, the number of carbon atoms is often specified preceding the group, for example, C1_s-alkyl means an alkyl group or radical having 1 to 6 carbon atoms. In general, for groups comprising two or more subgroups, the last named up is the radical ment point, for example, the substituent "aryl-C1alkyl-" means an aryl group which is bound to a 01alkyl- group, the latter of which is bound to the core or to the group to which the substituent is attached.

In case a compound of the present invention is ed in form of a al name and as a formula in case of any discrepancy the formula shall prevail.

An asterisk is may be used in rmulas to indicate the bond which is connected to the core molecule as defined.

The numeration of the atoms of a substituent starts with the atom which is closest to the core or to the group to which the substituent is attached.

For example, the term “3-carboxypropyl-group” represents the following substituent: 1 3 n the carboxy group is attached to the third carbon atom of the propyl group.

The terms “1 lpropyl- , 2,2—dimethylpropyl-“ or “cyclopropylmethyl-“ group represent the ing groups: 1 2 3 )\/ CH3 CH3 * H30 CH3 <1 1 2 3 ’ ’ .

The sk may be used in sub-formulas to indicate the bond which is connected to the core molecule as defined.

In a definition of a group the term "wherein each X, Y and Z group is optionally substituted with" and the like denotes that each group X, each group Y and each group Z either each as a separate group or each as part of a composed group may be substituted as defined. For e a definition "Rex denotes H, 01alkyl, 03 cycloalkyl, 03cycloalkyl-C1_3-alkyl or 01alkyl-O-, wherein each alkyl group is optionally substituted with one or more Lex." or the like means that in each of the beforementioned groups which comprise the term alkyl, i.e. in each of the groups C1- 3-alkyl, 03cycloalkyl-C1_3-alkyl and 01alkyl-O-, the alkyl moiety may be substituted with Lex as defined.

In the following the term bicyclic includes spirocyclic.

Unless specifically indicated, throughout the specification and the appended claims, a given chemical formula or name shall encompass tautomers and all stereo, optical and geometrical isomers (e.g. enantiomers, diastereomers, E/Z isomers etc...) and racemates thereof as well as mixtures in different proportions of the separate enantiomers, mixtures of diastereomers, or mixtures of any of the foregoing forms where such isomers and omers exist, as well as salts, ing pharmaceutically acceptable salts thereof and solvates thereof such as for instance 2017/060890 es including es of the free compounds or solvates of a salt of the compound.

The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or cation, and surate with a reasonable benefit/risk ratio.

As used herein, "pharmaceutically acceptable salts" refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or c salts of acidic residues such as carboxylic acids; and the like.

The ceutically acceptable salts of the present invention can be synthesized from the parent compound which ns a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a sufficient amount of the appropriate base or acid in water or in an organic t like ether, ethyl acetate, ethanol, isopropanol, or itrile, or a mixture thereof.

Salts of other acids than those mentioned above which for example are useful for purifying or isolating the compounds of the present invention also comprise a part of the invention.

The term halogen generally denotes fluorine, chlorine, bromine and iodine.

The term “C1_n-alkyl”, wherein n is an integer from 1 to n, either alone or in combination with another radical denotes an acyclic, saturated, branched or linear hydrocarbon radical with 1 to n C atoms. For example the term 01alkyl embraces the ls H30, H30-CH2—, H30-CH2—CH2—, H30-CH(CH3)—, H30-CH2—CH2—CH2—, H30-CH2—CH(CH3)—, H30-CH(CH3)—CH2—, H30-C(CH3)2—, H30-CH2—CH2—CH2—CH2—, 2—CH2—CH(CH3)—, H30-CH2—CH(CH3)-CH2-, H30-CH(CH3)—CH2—CH2—, ch— CH2—C(CH3)2—, H30-C(CH3)2—CH2—, H30-CH(CH3)—CH(CH3)— and ch-CHZCH (CHZCH3)-.

The term cycloalkyl”, wherein n is an integer 4 to n, either alone or in combination with another radical s a cyclic, saturated, unbranched hydrocarbon radical with 3 to n C atoms. The cyclic group may be mono-, bi-, tri- or yclic, most preferably monocyclic. Examples of such cycloalkyl groups include ropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclododecyl, bicyclo[3.2.1.]octyl, spiro[4.5]decyl, norpinyl, norbonyl, norcaryl, adamantyl, etc.

Many of the terms given above may be used repeatedly in the definition of a formula or group and in each case have one of the meanings given above, independently of one another.

All rests and substituents as defined hereinbefore and hereinafter may be substituted with one or more F atoms.

Pharmacological Activity The activity of the compounds of the invention may be demonstrated using the following AOC3 assay: AOC3 biochemical assay The MAO-GloT'VI Assay (commercial available from PROMEGA, #V1402) es a sensitive method for the measurement of monoamine oxidase (MAO) activity (Valley, M. P. et al., 2006, Anal. m. 359: 238-246) from a variety of tissues, biofluids or recombinant expressed or ed enzymes. As substrate a te of the beetle luciferin ((4S)—4,5-dihydro(6-hydroxybenzothiazolyl)thiazole-carboxylic acid) is used, which is oxidized at a primary amine moiety. After a spontaneous elimination and a catalyzed esterase reaction, the turnover of the luciferine by the luciferase is recorded as a signal of AOC3 activity.

For the determination of AOC3 activity or compound inhibition potency, the compound inhibitors are dissolved in DMSO and adjusted to the respective assay concentration with on buffer (50 mM HEPES, 5 mM KCI, 2 mM CGCIz, 1.4 mM MgCl2, 120 mM NaCl, 0.001% (v/v) Tween 20, 100 uM TCEP, pH 7.4). An aliquot of 3 uL of the compound dilution is added to a 384 well plate (Optiplate, PS, flat bottom, white, PERKIN ELMER, #6007290) with a final DMSO concentration of 6.6%.

Recombinant CHO cells, overexpressing the human (1500 cells/well), mouse (1000 cells/well) or rat (500 cells/well) AOC3 enzyme are diluted in reaction buffer and added in a volume of 15 uL to the wells. After incubation for 20 minutes at 37°C, 2 uL of MAO substrate (dissolved in DMSO at 16 mM, adjusted to assay concentration in reaction buffer to a final assay concentration of 20 uM) is added and further ted for 60 minutes at 37°C. The turnover of the substrate is determined by the addition of 20 uL of the detection-mix which was generated by the addition of reconstitution buffer with esterase (PROMEGA, #V1402) to the luciferine detection reagent (PROMEGA, #V1402). After an incubation period of 20 minutes, the luminescent signal is measured with on 2104 Multilabel Reader (PERKIN Alternative assays for the determination of the AOC3 enzymatic activity could be the extraction of 14C-labelled benzylamine reaction product or the Amplex Red Monoamine Oxidase reaction (Molecular , Netherlands) as described in Gella et al. , A. et al., 2013, J. Neural Transm. 120: 1015-1018).

The compounds of l formula (I) according to the invention for example have IC50 values below 5000 nM, particularly below 1000 nM, preferably below 300 nM, most preferably below 100 nM.

AOC1 biochemical assay The Amplex® Red Assay (available from Thermo Fisher Scientific) provides a sensitive method for the detection of H202 generated during enzymatic reactions like the amine oxidation catalyzed by AOC1. The assay reagent is a colorless ate (N-acetyl-3,7-dihydroxyphenoxazine) that reacts in a 1:1 stoichiometry with hydrogen peroxide (H202) to produce the fluorescent dye fin (7-hydroxyphenoxazin one, excitation/emission maxima=570l585 nm).

For the ination of AOC1 ty or compound AOC1 inhibition potency, the compound inhibitors are dissolved in DMSO and adjusted to the tive assay concentration with on buffer (100 mM sodiumphosphate, 0.05% Pluronic F-127 (#P3000MP Sigma-Aldrich), pH 7.4). An aliquot of 3 uL of the nd dilution is added to a 384 well plate (Optiplate, PS, flat bottom F, black, PERKIN ELMER, #6007270) in a DMSO concentration of 6.6%.

An AOC1 enzyme t (#8297-AO-010, R&D Systems) is thawed on ice, diluted in reaction buffer and added in a volume of 7 uL to the wells to give a final assay concentration of 1 ng/well. After incubation of inhibitor and enzyme for 30 minutes at 37°C, the enzymatic reaction is d with the addition of 10 uL of Amplex® Red reaction mix (final assay concentration: 100 mM sodiumphosphate, 120 uM Amplex® Red reagent (#A22177 Molecular Probes), 1.5 U/mL Horseradish Peroxidase (#P8375 Aldrich), 200 uM putrescine (#P7505 Sigma-Alrdich), 0.05% Pluronic F-127 (#P3000MP Sigma-Aldrich), pH 7.4, 37°C).

After an incubation for 30 minutes at 37°C the turnover of the substrate is determined directly (or after the addition of an excess of an amine-oxidase inhibitor) with a fluorescence reader (Ex 540nm/Em 590nm) like Envision 2104 Multilabel Reader (PERKIN ELMER).

In the following table the activity expressed as leo (nM) of compounds according to the invention is presented wherein the IC50 values are determined in the AOC3 and AOC1 assay as described hereinbefore. The term "Example" refers to the example s according to the following experimental section.

Table 1: Biological data of the compounds of the present invention as obtained in the AOC3 and AOC1 assays. _ 28 _ Example AOC3 |C50 AOC1 |C50 Example AOC3 |C50 AOC1 |C50 01 27 nM 7604 nM 20 5 nM 7207 nM 02 10 nM 8074 nM 21 4 nM 3192 nM 03 8 nM 8034 nM 22 3 nM 2374 nM 04 5 nM 1723 nM 23 2 nM 3817 nM 05 15 nM 2392 nM 24 4 nM 1585 nM 06 15 nM 10163 nM 25 3 nM 483 nM 07 5 nM 2011 nM 26 3 nM 2520 nM 08 4 nM 2689 nM 27 4 nM 3770 nM 09 7 nM 1415 nM 28 15 nM 3288 nM 11 nM 3478 nM 29 2 nM 659 nM 11 5 nM 2394 nM 30 3 nM 978 nM 12 5 nM 7530 nM 31 3 nM 612 nM 13 2 nM 1479 nM 32 2 nM 710 nM 14 3 nM 1336 nM 33 3 nM 899 nM 8 nM 5194 nM 34 2 nM 503 nM 16 9 nM 718 nM 35 3 nM 1022 nM 17 5 nM 3616 nM 36 5 nM 1153 nM 18 3 nM 1401 nM 37 3 nM 227 nM 19 9 nM n.D. 38 3 nM 322 nM AOC1 expression and enzymatic activity is mainly found in the gut, placenta and kidney. The enzyme catalyzes the oxidation of primary amines derived from nutrition and protects the duum from cardiometabolic effects of histamine, putrescine, tryptamine and cadaverine. Inhibition of AOC1 can lead to impaired tolerance to ingested histamine, ing in increased plasma and tissue ine-levels which can cause adverse events or undesirable side effects like decreased aterial pressure _ 29 _ and compensation by increased heart-rate, tachycardia, headache, flush, urticaria, pruritus, bronchospasm and cardiac arrest (Maintz L. and Novak N. 2007. Am. J.

Clin. Nutr. 85:1185-96). The consequence of A001 inhibition in combination with histamine intake has been demonstrated in experiments with pigs: After the injection of the A001 inhibitor aminoguanidine (100 mg/kg) and gavage of histamine (2 mg/kg) s experienced increased histamine blood levels accompanied with a drop of blood pressure, increased heart rate, flushing, ng and death (3 out of animals) er J. 1988. Agents and Actions, 23: 361-365) under the experimental conditions. Histamine intolerance in humans was associated to mutations in the promoter region of A001, leading to reduced mRNA expression and plasma AOC1 activity (Maintz et al. 2011. y 66: 893—902).

Therefore, it was an aim of the invention to provide compounds with a low activity on AOC1, in order to avoid such red side-effects.

Thus, the A001 activity was measured, and, suprisingly, it was found out that the pyridinyl compounds of the present invention exhibit an high selectivity s AOC1.

It has now been found out that, surprisingly, the compounds according to the present invention are more selective towards AOC1 than the corresponding prior art compounds as described in EP 2 695 881, Le. the replacement of the fluoro- substituted phenyl moiety (adjacent to the guanidine on) by a pyridinyl moiety results in compounds with a highly sed ivity towards AOC1, without affecting the activity towards AOC3. The selectivity towards AOC1 was tested according to the A001 assay as described above.

Table 2: Biological data of certain compounds of EP 2 695 881 (corresponding to WO 2012/124696) as obtained in the A003 and A001 assays as described above and comparison with the corresponding compounds of the invention.

Comparison leo |C50 nd of Structure AOC3 AOC1 present invention HZN EX. 5: H3C —\04</N \ HN>:NH |C50 AOC3: 15 nM N— >:0 6nM 60 nM |C50 AOC1: 2392 F 0 EX. 136, p.235 H HN 3 EX. 10: H04? \ Hf“ |C50 AOC3: 11 nM N— O>:O 6nM 97 nM |C50 AOC1: 3478 EX. 197, p. 243 EX. 13: H 3C\O ‘<>N 4</N \ HN>: NH |C50 AOC3: 2 nM N 1nM 100 nM |C50 AOC1: 1479 Ex.63,p.227 H2N EX. 14: OHM/N \ Hf“ |C50 AOC3: 3 nM N— go 1nM 174 nM F O |C50 AOC1: 1336 Ex.81,p.229 H 3C HN EX. 37: 0%NC>—\O 4</N \ HN>~ NH2 |C50 AOC3: 3 nM N— h 1nM 6 nM |C50 AOC1: 227 F 0 Ex.11,p.221 Comparison |C50 |C50 compound of Structure AOC3 AOC1 present invention <57 EX. 38: IC50AOC3: 3 nM N N HfNH \ 0 $04 >: 1 nM 8 nM _ |C50 AOC1: 322 N O F 0 Ex. 74, p. 229 In view of their y to inhibit AOC3, the compounds of general formula (I) according to the invention and the corresponding salts f are suitable for the treatment, including preventative treatment of all those diseases or conditions which may be ed or which are mediated by the inhibition of AOC3 activity.

Accordingly, the present invention relates to a compound of general formula (I) as a medicament.

Furthermore, the present invention relates to the use of a compound of general formula (I) for the treatment and/or prevention of diseases or conditions which are mediated by the inhibition of AOC3 in a patient, preferably in a human.

In yet another aspect the t invention s a method for treating, ing preventing a disease or condition mediated by the inhibition of AOC3 in a mammal that includes the step of administering to a t, preferably a human, in need of such treatment a therapeutically effective amount of a compound of the present invention, or a pharmaceutical composition thereof.

Diseases and conditions ed by tors of AOC3 embrace NASH (non- alcoholic steatohepatitis), pulmonary fibrosis, retinopathy or nephropathy.

According to one aspect the compounds of the present invention are particularly _ 32 _ suitable for treating atory diseases, such as vascular inflammatory diseases, arthritis, acute and chronic joint mation; eczema, such as atopic eczema, psoriasis ulcerative and rheumatoid psoriasis; pain, ularly musculoskeletal or nociceptive pain; inflammatory bowel disease, particularly non-infectious inflammatory bowel disease; multiple sclerosis; scleroderma, pulmonary diseases such as atory distress syndrome, asthma, pulmonary fibrosis, iodiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD) and idiopathic inflammatory disease; nephropathy, diabetic proteinuria, kidney fibrosis; diabetic retinopathy or diabetic oedema such as macular diabetic oedema; cancer, particularly melanoma and lymphoma; hepatocellular carcinoma, unspecified Colitis, rheumatoid s disease Colitis; y tract diseases, primary biliary cholangitis, primary sclerosing cholangitis, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver e (NAFLD), alcoholic liver disease, liver fibrosis, liver cirrhosis; ulcerative reperfusion injury, cerebral ischaemia and transplant rejection.

According to another aspect the compounds of the present ion are particularly suitable for ng matory diseases, such as vascular inflammatory diseases, arthritis and inflammatory bowel disease, particularly non-infectious inflammatory bowel disease; pulmonary fibrosis and iodiopathic pulmonary fibrosis; diabetic retinopathy or diabetic oedema such as macular diabetic oedema; ified Colitis, rheumatoid Crohn's disease s; y tract diseases, primary biliary cholangitis, primary sclerosing cholangitis, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), alcoholic liver e, liver fibrosis, and liver cirrhosis.

The dose range of the nds of general formula (I) applicable per day is y from 0.001 to 10 mg per kg body weight of the patient, ably from 0.01 to 8 mg per kg body weight of the patient. Each dosage unit may conveniently contain 0.1 to 1000 mg of the active substance, preferably it contains between 0.5 to 500 mg of the active substance.

The actual therapeutically effective amount or therapeutic dosage will of course depend on factors known by those skilled in the art such as age and weight of the patient, route of administration and severity of disease. In any case the combination will be administered at dosages and in a manner which allows a therapeutically effective amount to be red based upon the patient’s unique condition.

Pharmaceutical Compositions Suitable preparations for administering the compounds of formula (I) will be nt to those with ordinary skill in the art and include for example tablets, pills, es, suppositories, es, troches, solutions, syrups, elixirs, sachets, injectables, tives and powders etc. The content of the pharmaceutically active compound(s) is advantageously in the range from 0.1 to 90 wt.-%, for example from 1 to 70 wt.-% of the composition as a whole.

Suitable tablets may be obtained, for example, by mixing one or more compounds according to formula (I) with known excipients, for example inert diluents, carriers, disintegrants, adjuvants, surfactants, binders and/or lubricants. The tablets may also consist of several layers.

Combination Therapy The compounds of the invention may further be combined with one or more, ably one additional therapeutic agent. According to one embodiment the additional therapeutic agent is selected from the group of therapeutic agents useful in the treatment of diseases or conditions associated with the metabolic syndrom, es, obesity, cardiovascular diseases, NASH (non-alcoholic steatohepatitis), ary fibrosis, retinopathy and/or nephropathy.

Therefore a compound of the invention may be combined with one or more additional therapeutic agents selected from the group consisting of anti-obesity agents ding te suppressants), agents which lower blood glucose, anti-diabetic agents, agents for treating dyslipidemias, such as lipid lowering agents, anti- hypertensive , antiatherosclerotic agents, anti-inflammatory active ingredients, anti-fibrotic , agents for the treatment of malignant tumors, antithrombotic agents, anti-angiogenesis agents, agents for the treatment of heart failure and agents for the treatment of complications caused by es or associated with diabetes.

Preferably, compounds of the present invention and/or pharmaceutical compositions comprising a compound of the present invention optionally in combination with one or more additional therapeutic agents are stered in conjunction with se and/or a diet.

Therefore, in another aspect, this invention relates to the use of a compound according to the invention in combination with one or more additional therapeutic agents described hereinbefore and hereinafter for the treatment or prevention of diseases or conditions which may be affected or which are mediated by the tion of AOC3, in particular es or conditions as described hereinbefore and hereinafter.

In yet another aspect the present invention relates a method for treating, including preventing a disease or condition mediated by the inhibition of AOC3 in a patient that includes the step of administering to the t, preferably a human, in need of such treatment a therapeutically effective amount of a compound of the present invention in combination with a therapeutically effective amount of one or more additional therapeutic agents described in hereinbefore and hereinafter, The use of the compound according to the invention in combination with the onal therapeutic agent may take place simultaneously or at staggered times.

The compound ing to the invention and the one or more additional therapeutic agents may both be present together in one ation, for example a tablet or capsule, or separately in two identical or different ations, for e as a so- called kit-of-parts.

Consequently, in another aspect, this invention relates to a pharmaceutical com- position which comprises a compound ing to the invention and one or more additional therapeutic agents described hereinbefore and hereinafter, optionally together with one or more inert carriers and/or diluents.

Synthesis Schemes l methods of preparing the compounds of the invention are described in the experimental section.

The potent inhibitory effect of the compounds of the invention can be determined by in vitro enzyme assays as described in the experimental section.

The nds of the t invention may also be made by methods known in the art including those bed below and including ions within the skill of the art.

Scheme 1: HO. /OH xm+g\—>A\\ l\ l\ H N’ aw N’ OYNWNHZ OH AYN 1A/ OH d'x/ o NH R N R N M 1-2 1-3 (I) Compounds of the general formula I, wherein A and R1 are as previously defined, can be prepared via the process outlined in scheme 1 using a compound of the general formula 1-1, wherein X is a halogen, with an boronic acid or corresponding pinacolate 1-2, in presence of a palladium st and ligand and a base in appropriate solvents such as dioxane at a temperature between 0°C and 150°C (Suzuki-coupling, Chem. Rev., 1995, 95 (7), 2457). The reaction of the benzylic alcohol of the general formula 1-3, wherein A and R1 are as previously defined, in order to obtain a compound of the general formula I, wherein A and R1 are as usly defined, may be achieved via the acylation with CDI followed by on with a guanidine salt in an appropriate solvent such as DMF. If reasonable, the reaction sequence to obtain compounds of the general formula I can also be reversed.

Scheme 2: \ \ \ )AL\ N —> Al \ N —> Al \ N / 0 / / \ R1)\N 0 \ R1)\N 0H x N PG PG 2-1 2-2 1-3 Intermediates of the general formula 1-3, wherein A and R1 are as previously defined, can be prepared via the process outlined in scheme 2 using a compound of the general formula 2-1, wherein A is as previously defined and X is a suitable g group, such as halogen or S(=O)Me, and PG is a suitable protecting group, such as SitBuMez, and a nucleophile in presence of a base such as NaH, DIPEA or DBU in appropriate solvents such as THF and DCM at a temperature between 0°C and 150°C. To obtain the benzyl alcohol intermediate 1-3 wherein A and R1 are as previously defined, the protecting group has to be removed using le ions, for example TBAF or TFA in THF for the SitBuMeg group. In certain cases, the anidine moiety can also be ed as protecting group and compounds of the general formula I can be directly obtained in one step from the corresponding intermediate 2-1.

Scheme 3: R N R 3-1 3-2 1-2 ediates of the general formula 1-2, wherein A and R1 are as previously defined, can be prepared via the processes outlined in scheme 3 using a compound of the general formula 3-1, n A is as previously defined and X and Y are a halogen and R1-H is a nucleophile in presence of a base such as DIPEA in appropriate solvents such as itrile at a temperature between 0°C and 150°C. atively, zinc-reagents and Negishi—coupling conditions (Handbook of Organopalladium Chemistry for Organic Synthesis, (ed. Negishi, E.-|.), 1, 229-247, (John Wiley & Sons Inc, New York, 2002) can be used. To obtain the boronic acid or corresponding pinacol ester intermediate 1-2 wherein A and R1 are as previously defined a Suzuki- Miyaura Borylation (J. Am. Chem. Soc., 2002, 124, 8001) or a n-metal exchange followed by reaction with a suitable electrophile, using reagent such as n- BuLi and B(OiPr)3, can be used.

W0 2017/194453 _ 37 _ Scheme 4: H3O CH3 (,3 Ag< CH XXN/AfiI —’R1)\N/AfiI —’ A/j/ELO I 4-1 4-2 1-2 atively, the reaction of a compound of the general formula 4-1, wherein A is as previously defined and X is halogen and R1-H is a nucleophile in presence of a base such as K2003 in appropriate solvents such as acetonitrile at a temperature between 0°C and 150°C furnishes the intermediate 4-2, wherein A and R1 are as previously defined. To obtain the boronic acid pinacol ester intermediate 1-2 wherein A and R1 are as previously defined, the lr-catalized on as described by Hartwig et al (J.

Am. Chem. Soc., 2014, 136 (11), 4287) can be utilized (scheme 4).

Scheme 5: Ag<CH3 H3C CH3 (,3 CH 3 91$<CH3 A \ E3‘0 CH3 A \ 3‘0 CH3 )L —> / | x N ’ -1 1-2 Alternatively, the reaction of a compound of the general formula 5-1, wherein A is as previously described and X is halogen and R1-H is a nucleophile in presence of a base such as NEt3 in appropriate solvents such as dioxane at a temperature between 0°C and 150°C can be used to obtain intermediate 1-2, wherein A and R1 are as previously d (scheme 5).

The synthetic routes presented may rely on the use of protecting groups. For example, reactive groups present, such as hydroxy, carbonyl, carboxy, amino, alkylamino or imino, may be protected during the reaction by tional protecting groups which are cleaved again after the reaction. Suitable protecting groups for the respective onalities and their removal are well known to the one skilled in the art and are described in the literature of c synthesis. 2017/060890 The compounds of general formula I may be resolved into their enantiomers and/or diastereomers as mentioned before. Thus, for example, cis/trans mixtures may be resolved into their cis and trans isomers and racemic nds may be separated into their enantiomers.

The cis/trans mixtures may be resolved, for example, by chromatography into the cis and trans isomers thereof. The compounds of general formula I which occur as racemates may be separated by methods known per so into their optical antipodes and diastereomeric mixtures of nds of general formula I may be resolved into their diastereomers by taking advantage of their different physico-chemical properties using methods known per se, e.g. chromatography and/or fractional crystallization; if the compounds obtained thereafter are racemates, they may be resolved into the enantiomers as mentioned above.

The racemates are preferably resolved by column chromatography on chiral phases or by crystallization from an optically active solvent or by reacting with an lly active substance which forms salts or derivatives such as esters or amides with the racemic compound. Salts may be formed with enantiomerically pure acids for basic compounds and with enantiomerically pure bases for acidic compounds.

Diastereomeric derivatives are formed with enantiomerically pure auxiliary compounds, e.g. acids, their activated tives, or alcohols. Separation of the diastereomeric mixture of salts or derivatives thus obtained may be achieved by taking advantage of their different physico-chemical ties, e.g. differences in solubility; the free antipodes may be released from the pure diastereomeric salts or derivatives by the action of suitable agents. Optically active acids ly used for such a e as well as optically active ls applicable as auxiliary residues are known to those d in the art.

As mentioned above, the compounds of formula I may be converted into salts, particularly for pharmaceutical use into the pharmaceutically acceptable salts. As used herein, "pharmaceutically able salts" refer to derivatives of the disclosed compounds n the parent compound is modified by making acid or base salts thereof. _ 3g _ Experimental Part The es that follow are intended to illustrate the present invention without restricting it. The terms "ambient temperature" and "room temperature" are used interchangeably and ate a temperature of about 20 °C.

The hereinafter described compounds have been characterized through their teristic mass after ionisation in a mass-spectrometer and their retention time on an analytical HPLC.

List of Abbreviations ACN Acetonitrile aq. Aqueous °C Degree celsius CDI Di(imidazoly|)methanone DA Diode array DCM Dichloromethane DBU 1,8—Diazabicyclo[5.4.0]undecene DIPEA N-ethyl-N-isopropy|-propanamine DMF N,N-dimethylformamide eq Equivalent ESl-MS Electrospray tion mass spectrometry EtOAC/ EE Ethyl acetate FC FIash-cromatography, Si02 is used if no further details given GP General procedure h Hour HPLC High mance liquid chromatography KOAc Potassium acetate K2003 Potassium carbonate L Liter MeOH Methanol _ 40 _ min Minute ml Milliliter mp Melting point MS Mass um NaH Sodium hydride NaHC03 Sodium bicarbonate n.d. Not determined Pd(PPh3)4 Tetrakis(triphenylphosphine)palladium(0) Pd(dppf)C|2 [1,1 ’ -Bis(diphenylphosphino)ferrocene]dichloropalladium(|l) RT Room temperature (about 20°C) Rt Retention time TBAF Tetrabutylammonium fluoride TF / TFA Trifluoroacetic acid THF Tetrahydrofuran TLC ayer chromatography on Si02 XPhOS Pd G2 Chloro(2-dicyclohexylphosphino-2’ ,4’ ,6’ opropyl-1,1’ - biphenyl)[2-(2’ -amino-1,1’ -biphenyl)]palladium(ll) HPLC-A: Agilent 1200 with DA- and MS—Detector, Sunfire C18_3.0X30mm, 2.5 pm (Waters), 60°C Time [min] % Sol [H20 0.1% TFA] % Sol [ACN] Flow [ml/min] 0.0 97.0 3.0 2.2 0.2 97.0 3.0 2.2 1.2 0.0 100.0 2.2 1.25 0.0 100.0 3.0 1.4 0.0 100.0 3.0 HPLC-B: Waters Acquity with DA- and ector, Sunfire C18_2.1 X 30 mm, 2.5 pm (Waters), 60°C Time [min] % Sol [H20 0.1% TFA] % Sol [ACN] Flow [ml/min] 0.0 99.0 1.0 1.5 0.02 99.0 1.0 1.5 1.0 0.0 100.0 1.5 1.1 0.0 100.0 1.5 HPLC-C: Agilent 1200 with DA- and MS—detector, XBridge C18_3.0X30mm, 2.5 pm (Waters), 60°C Time [min] % Sol [H20 0.1% NH4OH] % Sol [ACN] Flow [ml/min] 0.0 97.0 3.0 2.2 0.2 97.0 3.0 2.2 1.2 0.0 100.0 2.2 1.25 0.0 100.0 3.0 1.4 0.0 100.0 3.0 HPLC-D: Waters Acquity with DA- and MS—Detector, XBridge BEH C18_2.1 X 30 mm, 1.7 pm (Waters), 60°C Time [min] % Sol [H20 0.1% TFA] % Sol [ACN] Flow [ml/min] 0.0 99.0 1.0 1.6 0.02 99.0 1.0 1.6 1.0 0.0 100.0 1.6 1.1 0.0 100.0 1.6 HPLC-E: Agilent 1100 with DA- and MS—detector, Sunfire 0X30mm, 2.5 pm s), 60°C Time [min] % Sol [H20 0.1% TFA] % Sol [ACN] Flow [ml/min] 0.0 98.0 2.0 2.0 1.2 0.0 100.0 2.0 1.4 0.0 100.0 2.0 HPLC-F: Waters Acquity with QDa-Detector, Sunfire C18_3.0 x 30 mm, 2.5 pm (Waters), 60°C Time [min] % Sol [H20 0.1% TFA] % Sol [ACN] Flow [ml/min] 0.0 95.0 5.0 1.5 1.3 0.0 100.0 1.5 1.5 0.0 100.0 1.5 1.6 95.0 5.0 1.5 HPLC-G: Waters Acquity with QDa-Detector, Sunfire C18_3.0 x 30 mm, 2.5 pm s), 60°C Time [min] % Sol [H20 0.1% NH4OH] % Sol [ACN] Flow [ml/min] 0.0 95.0 5.0 1.5 1.3 0.0 100.0 1.5 1.5 0.0 100.0 1.5 1.6 95.0 5.0 1.5 : Waters Acquity with QDa-Detector, Sunfire C18_3.0 x 30 mm, 2.5 pm (Waters), 40°C Time [min] % Sol [H20 0.1% TFA] % Sol [ACN 0.08% TFA] Flow [ml/min] 0.0 95.0 5.0 1.5 1.3 0.0 100.0 1.5 1.5 0.0 100.0 1.5 1.6 95.0 5.0 1.5 I. 1 5-[6-(tert-ButyI-dimethyI-silanyloxymethyl)-pyridinyI]methanesquinyI- pyrimidine O N “5%/ \ / \ H30 N— N O CH (CH3)23i7< H3C CH3 To a mixture of 10.00 g (53.19 mmol) 2-bromo(hydroxymethyl)pyridine, 8.69 g (127.65 mmol) imidazole and DMF 10.42 g (69.14 mmol) tert-butyl-chloro-dimethyl- silane are added and the mixture is stirred at RT overnight. The reaction mixture is d with EtOAc and washed with water, dried and evaporated. The crude product is purified by FC yielding 16 g 2-bromo(tert-butyl-dimethyl-silanyloxymethyl)- pyridine To a mixture of 1.04 g (3.24 mmol) 2-bromo(tert-butyl-dimethyl-silanyloxymethyl)- pyridine, 662 mg (3.89 mmol) (2-methylsulfanylpyrimidinyl)boronic acid, 4.3 ml (8.6 mmol) 2 M Na2C03 sol. in H20 and dioxane, 265 mg (0.325 mmol) f)C|2 * DCM is added and the reaction mixture is stirred at 90°C overnight. The reaction mixture is diluted with water and extracted with EtOAc. The organic phases are pooled and washed with water and brine, dried with MgSO4 and evaporated. The crude product is purified by FC yielding 1.05 g utyl-dimethyl-[[6-(2- sulfanylpyrimidinyl)pyridyl]methoxy]silane.

A mixture of 2.00 g (5.76 mmol) tert-butyl-dimethyl-[[6-(2-methylsulfanylpyrimidin yl)pyridyl]methoxy]silane and DCM is cooled in an ice bath and 1.32 g (5.76 mmol) 75% 3-chlorobenzenecarboperoxoic acid are slowly added and the e is stirred at 0°C for 1 h and at RT for 2 h. The reaction mixture is diluted with DCM and washed with saturated NaHC03 solution and water, dried with Na2804 and evaporated.

Yield: 2.03 g (97%), ESl-MS: m/z = 364 (M+H)+, Rt(HPLC): 1.19 min (HPLC-A) I.2 utyI-[[6-(2-chloropyrimidinyl)pyridyl]methony-dimethyI-silane N N O CH (CH3)23i7( H3C CH3 A mixture of 0.6 g (2 mmol) (6-bromopyridyl)methoxy-tert-butyl-dimethyl-silane (vide supra) and THF is cooled to -70°C and 0.9 ml 2.3 M solution of n-hexyl lithium in hexane (2.1 mmol) is added, followed by 2.0 ml 1 M solution of ZnC|2 in diethyl ether (2.0 mmol). The mixture is allowed to reach RT and d for 30 min. Then 0.1 g (0.1 mmol) Pd(PPh3)4 and 0.2 g (1 mmol) 2-chloroiodopyrimidine in THF is added. The mixture is stirred at RT overnight, diluted with sat. NaHC03-solution and extracted with EtOAc. The organic phases are pooled, dried and evaporated and the residue is purified by FC on aluminium oxide.

Yield: 0.1 g (30%), ESl-MS: m/z = 336/338 (M+H)+, Rt(HPLC): 1.33 min (HPLC-A) I.3 [6-(6-fluoropyridyl)pyridyl]methyl N-carbamimidoylcarbamate \ HN / \ F / O >\*NH2 _ N_ yN O H A mixture 0.4 g (1.47 mmol) of intermediate "M, 0.23 g (1.6 mmol) (6-fluoro l)boronic acid, 4 ml 1M K3PO4-solution in water (4 mmol) and 0.12 g (0.14 mmol) XPhos Pd G2 in dioxane are heated to 90°C for 2 h, then cooled to RT, diluted with water and extracted with EtOAc. The organic phases are pooled, washed with water and brine, dried and evaporated. The e is triturated with ether and filtered.

Yield: 0.22 g (52%), : m/z = 290 (M+H)+, C): 0.37 min (HPLC-B) The following Intermediates can be obtained according to the given references.

# Structure/Reference # Structure/Reference HO / ".50 'o "51 HOX W02012/66070 /98272 |||.50 OH Br \N III.1(6-bromopyridyl)methyl N-carbamimidoylcarbamate W0 2017/194453 To a mixture of 3.0 g (16.0 mmol) (6-bromopyridyl)methanol and DMF 3.9 g (24.1 mmol) CDI is added and the mixture is stirred at RT for 2h. Then 5.8 g (32.0 mmol) guanidine carbonate are added and the reaction mixture is stirred at RT overnight, then diluted with water and cooled in an ice bath. After 1h the precipitate is ed off, washed with cold water and dried.

Yield: 3.7 g (85%), ESl-MS: m/z = 273 (M+H)+, Rt(HPLC): 0.70 min C), mp=168-172°C.

IV. 1 2-(3-methoxyazetidinyI)(4,4, 5,5-tetramethyI-1,3,2-dioxaborolan yI)pyrimidine H30 N— O<:N4<\ )3[OH N A mixture of 1.4 g (10.92 mmol) 3-methoxy-azetidine hydrochloride, 2.9 g (12.10 mmol) 2-chloroiodo-pyrimidine, 3.0 ml (17.61 mmol) DIPEA and ACN are heated to 50°C overnight. The t is evaporated and the crude product purified by FC giving rise to 2.8 g 5-iodo(3-methoxyazetidinyl)pyrimidine.

A mixture of 0.5 g (1.72 mmol) (3-methoxyazetidinyl)pyrimidine, 0.6 g (2.23 mmol) bis(pinacolato)diborone, 0.5 g (5.30 mmol) KOAc, 71 mg (0.087 mmol) Pd(dppf)C|2 * DCM and dioxane is heated to 100°C overnight. After cooling to RT, the reaction e is filtered through a pad of Celite and evorated. The crude product is purified by FC.

Yield: 300 mg (84%), ESl-MS: m/z = 210 (M+H)+, Rt(HPLC): 0.25 min (HPLC-D) IV.2 (2,2-Difluoro-propyl)-[5-(4,4, 5,5-tetramethyI-[1,3,2]dioxaborolanyl)- pyrimidin-Z-yIJ-amine HF30 CH3 N— O ' CH . ~03 : s H / N 0 CH3 A mixture of 70 mg (0.29 mmol) 2-chloro(4,4,5,5-tetramethyl-1,3,2-dioxaborolan yI)pyrimidine, 42 mg (0.32 mmol) fluoro-propylamine hydrochloride, 0.13 ml (0.93 mmol) triethylamine and dioxane is heated to 90°C for 1 h. After cooling to RT the reaction mixture is diluted with aqueous NaCl solution. The precipitate is filtered off, washed with water and dried.

Yield: 110 mg (126%), ESl-MS: m/z = 218 (M+H)+, Rt(HPLC): 0.30 min (HPLC-B) IV.3 N,N-dimethyI(4,4, 5,5-tetramethyI-1,3,2-dioxaborolanyl)pyrimidin amine Hsc 4<N— IN \:>7B‘ CH3 N oim3 / H3C 0 A mixture of 22.5 ml (45.5 mmol) solution ofdimethylamine in THF, 3.0 g (15.5 mmol) robromo-pyrimidine and ACN are stirred at RT for 1h. The solvent is evaporated, water is added and the mixture is extracted with EtOAc. The organic phases are pooled, dried and evaporated yielding 3.2 g 5-bromo-N,N-dimethyl- dinamine.

A mixture of 0.5 g (2.48 mmol) 5-bromo-N,N-dimethyl-pyrimidinamine, 0.8 g (3.24 mmol) nacolato)diborone, 0.6 g (6.38 mmol) KOAc, 0.2 g (0.25 mmol) Pd(dppf)Cl2 * DCM and dioxane is heated to 100°C for 4.5 h. After cooling to RT, the reaction mixture is filtered through a pad of Celite and evorated, water is added and the mixture is extracted with EtOAc. The organic phases are pooled, dried and evaporated The crude product is purified by FC.

Yield: 0.6 g (96%), ESl-MS: m/z = 250 (M+H)+, Rt(HPLC): 0.22 min (HPLC-A) IV.4 2-tetrahydropyranyI(4,4,5,5-tetramethyI-1,3,2-dioxaborolan yI)pyrimidine A mixture of 1.0 g (3.5 mmol) 5-bromoiodo-pyrimidine, 0.2 g (0.18 mmol) Pd(PPh3)4 and THF is cooled to 0°C and 14 ml (7.0 mmol) 0.5 M solution of etrahydropyranyl)zinc is added, The mixture is allowed to reach RT and d overnight. Then additional Pd(PPh3)4 and 5 ml (2.5 mmol) 0.5 M solution of etrahydropyranyl)zinc is added and the mixture d at RT for 4 h, diluted with sat. NaHC03-solution and EtOAc, filtered through celite and extracted with EtOAc. The organic phases are pooled, washed with water and brine, dried and evaporated and the residue is purified by FC yielding 0.41 g 5-bromo tetrahydropyranyl-pyrimidine.

A mixture of 0.4 g (2.48 mmol) 5-bromotetrahydropyranyl-pyrimidine, 0.54 g (2.14 mmol) bis(pinacolato)diborone, 0.49 g (4.94 mmol) KOAc, 0.07 g (0.25 mmol) f)Cl2 and dioxane is heated to 90°C for 1.5 h. After cooling to RT, the reaction mixture is diluted with water and extracted with EtOAc. The organic phases are pooled, washed with water and brine and dried. Charcoal is added, the mixture is filtered h Celite and evaporated.

Yield: 0.4 g (84%), ESl-MS: m/z = 291 (M+H)+, Rt(HPLC): 0.30 min (HPLC-B) IV.5 2-propoxy(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)pyrimidine H3C CH3 H N— 0fl>78,/ ~O O:CH3 CH3 A mixture of 1.0 g (5.2 mmol) 2-chlorobromo-pyrimidine, 1.4 g (10.3 mmol) K2C03 and 10 ml n-propanol are stirred at RT for 48 h. The reaction mixture is diluted with water and EtOAc. The organic phase is washed with brine, dried and evaporated yielding 1.2 g opropoxy-pyrimidine.

The mixture of 0.5 g (2.00 mmol) opropoxy-pyrimidine, 0.6 g (2.20 mmol) bis(pinacolato)diborone, 0.4 g (4.00 mmol) KOAc, 0.2 g (0.20 mmol) Pd(dppf)Cl2 * DCM and dioxane is heated to 100°C for 2 h. After cooling to RT, the reaction mixture is diluted with EtOAc and filtered through Celite. The filtrate is evaporated and the residue ed by FC.

Yield: 0.5 g (85%), Rt(HPLC): 0.74 min (HPLC-A) IV. 6 2-(2,2-difluoropropoxy)(4,4, 5,5-tetramethyI-1,3,2-dioxaborolan yI)pyrimidine 2017/060890 _ 48 _ H3C CH3 0%,}Bbim:N_ 0 F ' CH A mixture of 9.7 g (100.6 mmol) 2,2-difluoropropanol and THF is cooled to 0°C and 4.1 g (92.9 mmol) 60% NaH are added in small portions. The reaction mixture is allowed to reach RT and stirred for 1h, then cooled to 0°C and 15.0 g (77.4 mmol) 2- bromo-pyrimidine in THF is added. The reaction mixture is stirred for 2 h at RT and then d with water and EtOAc. The organic phase is dried and evaporated. The residue is purified by FC giving rise to 17.3 g 5-bromo(2,2- difluoropropoxy)pyrimidine.

The mixture of 9.5 g (37.5 mmol) 5-bromo(2,2-difluoropropoxy)pyrimidine, 12.4 g (48.8 mmol) bis(pinacolato)diborone, 9.6 g (95.5 mmol) KOAc, 0.9 g (1.1 mmol) Pd(dppf)C|2 * DCM and dioxane is heated to 100°C for 5 h. After cooling to RT, the reaction mixture is diluted with water and EtOAc. To the organic phase, charcoal, NaSO4 and silica gel is added and the e is filtered through celite. The filtrate is evaporated and the residue is triturated with petrol ether, filtered and dried.

Yield: 9.5 g (84%), ESl-MS: m/z = 301 (M+H)+, Rt(HPLC): 0.41 min B) IV. 7 3-[[5-(4,4, 5,5-tetramethyI-1,3,2-dioxaborolanyl)pyrimidin yI]oxymethyI]isoxazoIe W CH3 / N_ 0 O4 ' CH N 0%\ ya i 3 N 0 CH3 A mixture of 10.0 g (100.9 mmol) isoxazolylmethanol and THF is cooled to 0°C and 4.0 g (100.9 mmol) 60% NaH are added in small portions. The reaction mixture is stirred for 45 min, and then 16.4 g (84.6 mmol) 2-chlorobromo-pyrimidine in DMF is added. The reaction mixture is stirred for 45 min at RT, then cooled to 0°C and diluted with water. The precipitate is filtered off, washed with water and dried yielding 20.1 g 3-[(5-bromopyrimidinyl)oxymethyl]isoxazole.

The e of 20.1 g (78.5 mmol) 3-[(5-bromopyrimidinyl)oxymethyl]isoxazole, 26.2 g (102.1 mmol) bis(pinacolato)diborone, 20.0 g (204.2 mmol) KOAc, 1.6 g (2.0 mmol) Pd(dppf)C|2 * DCM and dioxane is heated to 100°C for 30 min. After cooling to RT, the reaction mixture is diluted with water and extracted with EtOAc. The organic phases are , charcoal is added and the mixture is filtered. The filtrate is evaporated and the residue is triturated with n-heptane, filtered and dried.

Yield: 17.5 g (74%), ESl-MS: m/z = 304 (M+H)+, C): 0.61 min (HPLC-A) IV.8 [2-[(1-quorocycIopropyI)methonypyrimidinyl]boronic acid $Og<lfl:/>7B‘OHN— [OH A mixture of 391 mg (4.3 mmol) (1-fluorocyclopropyl)methanol and THF is cooled to 0°C and 174 mg (4.3 mmol) 60% NaH are added in small portions. The reaction mixture is stirred for 30 min, and then 700 mg (3.6 mmol) 2-chlorobromo- pyrimidine in DMF is added. The reaction mixture is stirred for 30 min at RT, then d with water and extracted with DCM. The organic phases are , dried and evaporated furnishing 856 mg 5-bromo[(1-fluorocyclopropyl)methoxy]pyrimidine.

The mixture of 428 mg (1.7 mmol) 5-bromo[(1-f|uorocyclopropyl)methoxy]- pyrimidine, 578 mg (2.3 mmol) nacolato)diborone, 442 mg (4.5 mmol) KOAc, 142 g (0.2 mmol) Pd(dppf)C|2 * DCM and dioxane is heated to 100°C for 1 h. After cooling to RT, the reaction mixture is diluted with water and extracted with EtOAc.

The organic phases are pooled, dried and evaporated Yield: 370 mg, ESl-MS: m/z = 213 (M+H)+, Rt(HPLC): 0.71 min (HPLC-A) IV.9 5-(4,4,5,5-tetramethyI-1,3,2-dioxaborolanyI)(4,4,4- trifluorobutoxy)pyrimidine h CH3 F N_ 0 < ' CH N 0 CH3 A mixture of 3.5 g (27.5 mmol) 4,4,4-trifluorobutano|, 4.8 g (25.0 mmol) 2-chloro bromo-pyrimidine, 12.2 g (37.5 mmol) Cs2C03 is d for 2h at RT, then heated to 50°C for 8 h then cooled to RT and stirred overnight. The mixture is diluted with ice cold water and the precipitate is filtered off and washed with water, then dissolved in W0 2017/194453 _ 50 _ EtOAc, washed with brine, dried and evaporated. The e is triturated with heptane at 0°C filtered and dried, giving rise to 5.0 g 5-bromo(4,4,4- trifluorobutoxy)pyrimidine.

The mixture of 3.0 g (10.5 mmol) o(4,4,4-trifluorobutoxy)pyrimidine, 3.5 g (13.7 mmol) bis(pinacolato)diborone, 2.7 g (27.4 mmol) KOAc, 0.3 g (0.3 mmol) Pd(dppf)C|2 * DCM and dioxane is heated to 100°C for 5 h. After cooling to RT, the reaction mixture is diluted with water and EtOAc. To the organic phase, charcoal and NaSO4 is added and the mixture is filtered through celite. The filtrate is evaporated and the residue is triturated with petrol ether, filtered and dried.

Yield: 3.0 g (86%), Rt(HPLC): 0.85 min (HPLC-A) The following Intermediates are obtained in similar manner as described for |V.3 (A), |V.2 (B), |V.6 (C) given in column GP. s are given in the column synthesis comment, the retention-time and mass (ESl-MS m/z M+H+) determined by HPLC-MS are given in the s MS and R.

IV Structure GP MS Synthesis Comment m CH3 / N_ O Os ”A )8. i043, CH 0.26 min.

|V.25 N B 221 1 h 90 c0 N O HPLC-B N 0 ’ ‘ y' CH HC-O 026 min |V.26 N 3 - 3 / B CH3 A 294 1000o H30, flu .0 HPLC-A |V.27 QO N4<\:/>*Bl iota,N 0 074 min B 320 - 1h 100°C HPLC-A , .

H3C N o CHCH3 Q CH N— '0 |V28 5H 0'26 mi” ' ,NK )8. B 224 3h100°C CH3 HPLC-B H3C N o 3 _ 51 _ 3 >/,N/\:>_\ CH3 N_ TLC: DCM/MeOH IV.29 o 0%}3‘ :83? c 20:1 N 0 3 Rf=o.4 TLC' PE/EtOA I C |V.30 o/—\N%N}B'O CH3 . , N / CH3 A 292 3:1 CH3 Rf=0.4 N 0 ’ ‘ |V.31 HC—o N 3 067 min - 3 H4<?\l}' B 280 / bid-I3 A 3h1OOC° HPLOC in]? CH N_ ,0 0.37 min |V.32 C 388 1h95C0 O 0%}3‘ ions HPLOD N O CH3 The following Intermediates are commercially available or can be obtained according to the given references.

# Structure/Reference # Structure/Reference H C“cos:N OH H Cso}.N OH |V.50 N‘ OH |V.51 N‘ OH J. Med. Chem, 2010 Vol. 53, , Bioorg. Med. Chem. Lett, #1,77 2010, vol.20, #23, 7046 CH3 3 N_ O HSCA<?\l:/>7B‘OiCH:N— O , CH , Q.

My :3/ 0 CH3 IV.52 IV.53 CH3 Ark Pharm, Inc, 1840 J. Am. Chem. Soc., 2014, Vol.

Industrial Drive, Suite 120, 136, # 7 Libertyville, IL 60048, USA General Procedure A. 1 1St step substitution (S):1.0 eq ediate | given eq intermediate IV and 3 eq DBU in DCM are added. The mixture is held at the given temperature for the given time.

W0 2017/194453 _ 52 _ 2nd step deprotection (D): 40 eq TFA are added and the e is held at the given temperature for the given time, then evaporated and purified by HPLC. 3rd step acylguanidine formation (A): To a e of 1.0 eq benzyl alcohol intermediate and DMF 2.0 eq CDI is added and the reaction mixture is stirred overnight. Then 2.0 eq guanidine carbonate are added and the mixture is stirred at RT for the given time. The reaction mixture is diluted with MeOH, DMF and acidified with TFA, filtered and purified by HPLC.

General ure A.2 1St step substitution (S): A mixture of 1.1 eq alcohol or intermediate II and THF 1.1 eq 60% NaH is added and the mixture is d for 10 min. 1.0 eq intermediate | is added and the mixture is held at the given temperature for the given time, then diluted with water and extracted with EtOAc. The organic phases are pooled, washed with water and brine and ated. 2nd step deprotection (D): The intermediate from step 1 is dissolved in THF and 1.5 eq TBAF in THF is added and the mixture is held at the given temperature for the given time, then diluted with water and extracted with EtOAc. The organic phases are pooled, washed with water and brine and evaporated. 3rd step acylguanidine formation (A): To a mixture of 1.0 eq benzyl alcohol intermediate from step 2 and DMF 1.5 eq CDI is added and the reaction mixture is d for 1h at RT. Then 2.0 eq guanidine carbonate are added and the mixture is stirred at RT for the given time. The reaction mixture is ied with TFA, filtered and purified by HPLC.

General Procedure A3 A mixture of 5.0 eq nucleophile and THF is cooled to 0°C and 3 eq 60% NaH is added, then warmed to RT and 1.0 eq of intermediate ||| dissolved in DMF is added and the mixture held at the given temperature for the given time. The reaction mixture is concentrated and diluted with water. The precipitate is filtered, washed and dried. Alternatively the crude product is purified by HPLC after concentration.

General Procedure B. 1 1St step ng (C):1.0 eq intermediate I, 1.0 eq intermediate IV and 2.0 eq 2M Na2C03 solution 0.10 eq bis(triphenylphosphine)palladium(ll)chloride in dioxane are heated to the given temperature for the given time. The resulting benzyl alcohol intermediate is purified by FC or HPLC. 2nd step acylguanidine formation (A): To a mixture of 1.0 eq benzyl alcohol intermediate and DMF 1.5 eq CDI is added and the reaction e is stirred for 2 h at RT. Then 2.0 eq guanidine carbonate are added and the mixture is stirred at RT for the given time. The reaction mixture is diluted with MeOH, DMF and acidified with TFA, filtered and purified by HPLC.

General Procedure 3.2 1.0 eq of intermediate III 1.1 eq intermediate IV and 3.5 eq K3PO4 0.1 eq XPhos Pd G2 in dioxane are heated to the given temperature for the given time. The reaction mixture is filterd h a MP SPE cartridge and ed by HPLC.

General Procedure 3.3 1.0 eq of intermediate III 1.5 eq ediate IV and 3.0 eq K3PO4 0.05 eq XPhos Pd G2 in dioxane/water (ca. 5:1) are heated to the given temperature for the given time.

The reaction mixture is ed by HPLC.

The following examples in table 3 (example number given in column #) are prepared according to general procedures A or B and as described below. Details for the general procedures are given in the column synthesis comment, the retention-time and mass (ESl-MS m/z M+H+) determined by HPLC-MS are given in the columns RT and MS.

Tab|e3 # Structure GP Start'fig [min] Synthes's maternal (HPLC Comment method) H304 \ / \ HN>:NH ”"1 01 B3' 0'31287 2h 100°C N— >:o |V.52 (B) ’ HZN C: 1 h, 100°C HC\ N A:2eq 0% \ / \ >:NH HN 111.50 0.34 02 B1 303 ine N_ N— >:0 ' |V.50 (B) carbonate, 0 1.1 eq CDI, >_</:_\ / _\ :w ”H 0.38 03 H:O>: 83 313 2h,100Co N53 (B) H3C N :N4< \ / \ HN>:NH ”L1 0.68 04 >:0 B3 2h 100°C H30 N— N— ' 316 |V.3 (A) ’ H3C H2N>: NH S: overnight, / \ HN 05 104/N \ 1.1 0.75 RT A1 317 ' N— N— >:0 ethanol (A) D: 2h, RT 0 A:3h, RT H3C N \ / \ HN>:NH 06 \54 ”"1 0'77 B3 319 1h 100°C N— N— >20 - mm (A) ’ H3C HZN ‘—\ N NH S: overni9 ht, 0% \ / \ H 07 A11 0'51331RT - N N— >:o pggloa' (F) D: 3h, RT 0 A: 3h, RT . .

# Structure GP Start'fig [min] s's maternal (.4ch t method) \\\_\ HZN S: overnight, N NH |.1 08 0% \ / \ HN A.1 but 00:1; 341 §T3h RT N_ N_ >:0 yn'1'0' A53h’RT' 0 ’ H3C—O ‘—\ N_ _ H2N>: NH HN HN 09 %N\ / \ / ”L1 0.69 o B.3 346 N >:O 1.5h,1OOC 1v.31 (A) H3C_O \_\ HZN N FNH "1 0% \ / \HN 3- 4d RT 2- 0.41 ' ’ N_ N_ >CO A.1methOXy 347 EASE; 0 -ethanol ’ F HN )_\ 1.1 N NH H3c 04/ \ / \ HN (2R)—2— 3: 84h, RTD: N_ N_ >:0 A.1f|uoro- ('F) 349 3h, RT propan- A: 2h, RT 1-ol O4N \ / \ N_ N— 0 111.1 0.36 12 B3 357 3h,1OOCo >fNH 1v.4 (B) O >7NH2 HC N NH 3‘ H2N>: / \ / \ 0:1.5 h, HN 111.50 0.69 13 0%)%N_ o N_ >:O B.1 3581000 1v.1 (A) A: overnlght_ j \ / \ >:NH O N HN 1110_5 038_ (131:3(365132 14 3’ \—/ N— N— >:0 8'1 358 1v.30 (B) 100°c3h 0 A: overnight W0 2017/194453 starting # Structure GP [min] Synthesis material (HPLC Comment method) 00 1.1 N NH (3S)- S: 4d, RT \ / \ 0% HA; A.1tegfohy' 359 D. 1h, RT N_ N_ O 3,382 A' 3h’ RT furan H3C—O N NH \ H2N>: N4/ \ / \ HN ”L1 0.4 16 H3C/ B.3 360 1.5h,1OOC, N_ N_ >:O |V.26 (A) gm HN 2 (1- ' N NH S. ght,' / \ / \ fluoro- 17 0%“ N_ “1%0 A.1 cyclo- (2F? 361 373,] RT pmpy')' 0 A: 3h, RT metha- ' ’ F HN 2 L3 F /N \ / \ HN>:NH 22- 18 CH3 O _ A.3dif|uoro- N_ >: 0 (i3) 366 overnight, RT propan- 1-ol F HZN ”1%F \ / \ >:NH 19 F HN ”"1 04 _ >:o B.2 366 3h,90°C N N |V.2 (B) F HZN F N_ N_ >20 |uoro- (i—i) 367 D: 1h, RT propan- A. 3h, RT 1-ol >:NH S:3h, RT \ \ / HN 21 %/N b{/ |.2 0.39 D: overnight, A2 368 N >:O ”51 (B) RT 0 A: overnight 2017/060890 # Structure GP Start'fig [min] Synthes's maternal (HPLC Comment method) F HZN H3C4»—\ NH / _\HN>: ”"1 0'35 22 HN%_\ H:o>: B2' 359 3h 90°C |V.25 (B) ’ org—k HZN \ / \ HN>:NH isoxa- 23 ' _ A.3 zoI >:o 369 N overnight, RT O ylme- thanol (LN>_\ |.1 0:_%/ \ / _\H isoxa- S:4d, RT 24 HN%:H A.1 zoI 00:35 370 D:1h, RT 0 ylme- A:3h, RT thanol C,N:_%/ \ / \ 11:“): ”H 0.75 HN>:O B.3 372 1.5h,1OOCo |V.28 (A) HN [mm- F ‘b—\ N NH2 22- S: overnight, 04</ \ / \ HN A1olifiuoro- 0.53 RT 379 ' N— N— }o cyclo- (F) D: 3h, RT 0 ]— A: 3h, RT methanol E HN HN): (hydro- S. overnl. NH _ —\04</N 9 ht, \ / \ Xyme‘ 0.56 RT 27 IN 382 N— N— }0 A-1éhyl')' (G) D:3h, RT VC 0' 0 A: 3h RT butane— ’ carbonitrile # ure GP Start'fig [min] Synthes's maternal (HPLC Comment method) ’//>—</ CH3 HZN N >:NH 3: 3h, RT O‘N / \ 28 0% \ |.2 D:overnight, >:0 A2 N— N— ' 0.41384 ”.50 (B) RT 0 A: overnight NQjO%N\ W H \ / \ HNFNH l- 3: 84h, RT 0 43 29 }o A.1 5-yl- 'F 386 D: 3h, RT N_ N_ ha- ( ) A- 2h RT 0 mitol ’ F HN sjjoj 2 L1 \ / \ thiazol- 3: 84h, RT HN 043 ' _ A.1 N N 0 4-yl- 386 D: 3h, RT metha- A' 2h, RT [S HN \>—\ N NH H 0% \ / \ HNF thiézol- 045 Si84h’RT 31 ' N_ N_ }o A.1 386 D: 3h, RT Z'y'me' (F) A- 2h RT 0 thanol ’ QO HZN N NH / \ / \ >: ”H 0.76 32 N o HN B3 386 1h,1OOC H35 %N_ |V.27 N_ (A) O/\:>—\O%}V HZN |.1 \ / \ HN £335; S:4d, RT N N_ }o A'1pyran 387 gignfil O ylme- ' ’ thanol N \ HZN |.1 | 1%0431 \ / \ HNFNH thiadi- 3: 84h, RT N_ N_ }o A.1azol ('F) 387 D: 3h, RT ylme- A- 2h, RT thanol W0 2017/194453 # Structure GP Start'rlg [mini Synthes's maternal (HPLC Comment method) /\>_\ HZN H N NH :N 04</ \ / \ thiadi- S:84h, RT HN 043 N N_ >:O A.1azol (F) 387 D: 3h, RT 0 ylme- A: 2h, RT thanol F H H N S' overnight N >:NH A1ti‘l4’4- 0'58 RT 36 0% \ / \ 399 HN orfi' (F) D:3h, RT ”an" N N— >:o A:3h,RT C:3eq HZN lll.50 0.38 N82C03, 37 8'1 N |V.29 (B) 428100°C3h \ / \ >:NH 04 HN A: ght N— N— e0 HZN |||.1 0.42 38 E >:NH B.2 454 1h 80Co N |V.32 / \ (D) O’</ \ N— N— >:O Example 03: [6-(2-cyclopropylpyrimidinyl)pyridyl]methyl N-carb- amimidoylcarbamate A mixture of 1.0 eq of intermediate "L1, 1.1 eq intermediate |V.53, 3.0 eq K3PO4 and 0.07 eq XPhos Pd G2 in dioxane/water (ca. 5:1) are heated to 100°C for 2 h. After cooling to RT the solvent is evaporated in taken up in a mixture of MeOH and DCM, 2017/060890 _ 60 _ filtered through a PL-thiol cartridge and evaporated. The crude product is purified by HPLC.

ESI-MS: m/z = 313 (M+H)+, Rt(HPLC): 0.39 min (HPLC-B) Example 07: [6-(2-propoxypyrimidinyl)pyridyl]methyl N-carbamimidoyl- carbamate A gentle stream of argon is passed through a mixture of 1.0 eq of intermediate "L1, 1.1 eq intermediate |V.5 and 2.5 eq K3PO4 in dioxane/water (ca. 5:1). Then 0.1 eq XPhos Pd G2 are added and the mixture heated to 100°C for 1 h. After cooling to RT the solvent is evaporated and the crude product is purified by FC.

ESI-MS: m/z = 331 (M+H)+, Rt(HPLC): 0.81 min A) e 08: [6-(2-butynoxypyrimidinyl)pyridyl]methyl N- carbamimidoylcarbamate 3.0 eq DBU are added to a mixture of 3.0 eq 3-butynol and DCM. After 1 h at RT, 1.0 eq of intermediate L1 in DCM is added and the mixture is d at RT for 3 h, then diluted with DCM and washed with NaHC03 solution and brine, dried and evaporated. Giving rise to crude tert-butyl-[[6-(2-butynoxypyrimidinyl)—2- pyridyl]methoxy]-dimethyl-silane S: m/z = 370 (M+H)+, Rt(HPLC): 1.26 min (HPLC-C)). THF and 1.5 eq TBAF are added and the mixture is stirred at RT for 20 min. The solvent is evaporated and the residue purified by FC, giving rise to [6-(2- butynoxypyrimidinyl)pyridyl]methanol (ESl-MS: m/z = 256 (M+H)+, Rt(HPLC): 0.80 min (HPLC-C)).

To a mixture of 1.0 eq [6-(2-butynoxypyrimidinyl)pyridyl]methanol and DMF, 1.5 eq CDI is added and the mixture is stirred for 2 h at RT, then 2.0 eq guanidine ate are added and stirring is continued overnight and then diluted with water.

The precipitate is filtered off and dried, triturated with ether and ed, then with MeOH and filtered and dried.

ESI-MS: m/z = 341 (M+H)+, Rt(HPLC): 0.79 min (HPLC-C) Example 1 7: [6-[2-[(1-quorocycIopropyI)methonypyrimidinyl]pyridyl]- methyl N-carbamimidoylcarbamate A gentle stream of argon is passed through a mixture of 1.0 eq intermediate "M, 1.11 eq intermediate |V.8 and 2.0 eq K3PO4 in dioxane/water (ca. 5:1). Then 0.1 eq XPhos Pd G2 are added and the mixture heated to 100°C for 30 min. After g to RT the reaction mixture is diluted with water and ted with EtOAc. The organic phases are pooled, dried and evaporated and the crude product is ed by FC. : m/z = 361 (M+H)+, Rt(HPLC): 0.75 min (HPLC-A) Example 20: [6-[2-(2,2-difluoropropoxy)pyrimidinyI]pyridyl]methyl N- carbamimidoylcarbamate A mixture of 1.0 eq (6-bromopyridyl)methanol, 1.1 eq intermediate |V.6 and 2.5 eq K3PO4 in dioxane/water (ca. 5:1) and 0.05 eq XPhos Pd G2 is heated to 100°C for 1 h. After g to RT the organic phases is separated and evaporated. The resulting crude product is purified by FC, furnishing [6-[2-(2,2-difluoropropoxy)pyrimidinyl] pyridyl]methanol (ESl-MS: m/z = 282 (M+H)+, Rt(HPLC): 0.85 min (HPLC-A)).

To a mixture of 1.0 eq [6-[2-(2,2-difluoropropoxy)pyrimidinyl]pyridyl]methanol and DMF, 1.5 eq CDI is added and the mixture is stirred for 2 h at RT, then 2.0 eq guanidine carbonate are added and stirring is continued overnight and then diluted with ice-cold water. The precipitate is filtered off and recrystallized from 95% EtOH, filtered off and dried.

ESI-MS: m/z = 367 (M+H)+, Rt(HPLC): 0.80 min (HPLC-A), mp: 195°C, Rf(TLC): 0.20 (DCM/MeOH/NH4OH 9:1 :0.01) Example 24: [6-[2-(isoxazoIylmethoxy)pyrimidinyl]pyridyl]methyl N- imidoylcarbamate A mixture of 1.0 eq intermediate "M, 1.10 eq intermediate NJ, 2.0 eq K3PO4 and 0.1 eq XPhos Pd G2 in e/water (ca. 5:1) is heated to 100°C for 30 min. After cooling to RT the reaction mixture is diluted with water and extracted with EtOAc. The 2017/060890 organic phases are pooled, dried and evaporated and the crude t is purified by FC, then triturated with ether, filtered and dried.

ESI-MS: m/z = 370 (M+H)+, Rt(HPLC): 0.75 min (HPLC-C), mp: 183°C, Rf(TLC): 0.18 (DCM/MeOH 9:1) Example 26: [6-[2-[[(1R)-2,2-difluorocyclopropyl]methoxy]pyrimidinyl] pyridyIJmethyI N-carbamimidoylcarbamate 3.0 eq DBU are added to a mixture of 3.0 eq [(1R)-2,2-difluorocyclopropyl]methanol and DCM. After 1.5 h at RT, 1.0 eq of ediate L1 is added and the mixture is stirred at RT overnight. The intermediate tert-butyl-[[6-[2-[[(1R)-2,2-difluorocyclo- propyl]-methoxy]pyrimidinyl]—2-pyridyl]methoxy]-dimethyl-silane (ESl-MS: m/z = 408 (M+H)+, Rt(HPLC): 1.33 min (HPLC-A)) is not isolated. 45 eq TFA are added to the reaction mixture and stirring is continued for 2 h at RT. The solvent is evaporated and the e purified by HPLC, giving rise to [6-[2-[[(1R)-2,2-difluorocyclopropyl]- methoxy]-pyrimidinyl]pyridyl]methanol (ESl-MS: m/z = 294 (M+H)+, Rt(HPLC): 0.86 min (HPLC-A)).

To a mixture of 1.0 eq [6-[2-[[(1R)-2,2-difluorocyclopropyl]methoxy]pyrimidinyl]—2- pyridyl]methanol and DMF, 1.44 eq CDI is added and the e is stirred at RT overnight, then 1.44 eq guanidine carbonate are added and stirring is continued for 3h. The reaction mixture is d with water and stirred for 2 h. The precipitate is ed off and dried.

ESI-MS: m/z = 379 (M+H)+, Rt(HPLC): 0.82 min (HPLC-A) mp: 6°C, Rf(TLC): 0.30 (DCM/MeOH/NH4OH 9:1 :0.01) Example 36: [6-[2-(4,4,4-trifluorobutoxy)pyrimidinyl]pyridyl]methyl N- carbamimidoylcarbamate A mixture of 1.0 eq (6-bromopyridyl)methanol, 1.1 eq intermediate |V.9 and 2.0 eq K3PO4 in dioxane/water (ca. 5:1) and 0.04 eq XPhos Pd G2 is heated to 100°C for 1 h. After cooling to RT the mixture is diluted with ice cold water and extracted with EtOAc. The organic phases are pooled washed with brine, dried and evaporated.

The resulting crude product is purified by F0, (4,4,4-trifluorobutoxy)pyrimidin y|]pyridy|]methano| (ESI-MS: m/z = 314 (M+H)+, Rt(HPLC): 0.91 min (HPLC-A)).

To a mixture of 1.0 eq [6-[2—(4,4,4-trifluorobutoxy)pyrimidiny|]pyridy|]methanol and DMF, 1.5 eq CDI is added and the mixture is stirred for 2 h at RT, then 2.0 eq guanidine carbonate are added and stirring is continued for 4 h and then diluted with ice-cold water. The itate is filtered off and dried.

ESI-MS: m/z = 399 (M+H)+, Rt(HPLC): 0.85 min (HPLC-A), mp: 194-197°C, Rf(TLC): 0.35 (DCM/MeOH/NH4OH 9:1 :0.01) Claims 1. A compound of formula (I) wherein A isNorCH; R1 is selected from the group ting of C1_s-alkyl, 03cycloalkyl, heterocyclyl, -O-R2, -S-R2, -NH-R2 and -N(R2)2, wherein each R2 is independently selected from the group ting of C1-e-alkyl, 03cycloalkyl, heterocyclyl, -(C1_2-alkyl)—(Cgcycloalkyl), -(C1_ 2-alkyl)-heterocyclyl, -(C1_2-alkyl)-aryl, -(C1_2-alkyl)-heteroaryl and —(C1 alkyl)—CECH; n each heterocyclyl of R1 and R2 is a 4- to 7-membered saturated carbocyclic group, in which 1 or 2 CHg-moieties are independently of each other replaced by an atom or group selected from NH, O, S, -S(=O)-, -S(=O)2- or—C(=O)—; and wherein each aryl is ed from the group consisting of phenyl and naphthyl; and wherein each heteroaryl is a 5- or 6—membered heteroaromatic ring which contains 1, 2 or 3 heteroatoms independently selected from =N-, -NH-, -O- and –S-, wherein in heteroaromatic groups containing a –CH=N- unit, this group is optionally replaced by –NH-C(=O)-; and wherein each alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl group of R1 and R2 is optionally independently substituted with one or more F, Cl, CN, OH, C1alkyl, -O-(C1- 3-alkyl), –C(=O)-(C1alkyl) and –C(=O)-(C3cycloalkyl); wherein each of the above-mentioned alkyl groups may be linear or branched and n the alkyl groups mentioned in each of the above-mentioned tions, if not specified otherwise, may be substituted by one or more F; or a salt thereof. 2. A compound of formula (I) according to claim 1, wherein R1 is C1alkyl, C3 cycloalkyl, heterocyclyl, -O-R2, -S-R2, -NH-R2 or -N(R2)2; wherein each cyclyl is a 4- to 6-membered saturated carbocyclic group, in which 1 or 2 CH2-moieties are replaced by a heteroatom selected from NH, O or S; and wherein each alkyl, cycloalkyl or heterocyclyl group is optionally independently substituted with 1 to 5 F and / or 1 to 3 tuents independently selected from the group ting of Cl, CN, OH, C1alkyl, alkyl), –C(=O)-(C1alkyl) and –C(=O)- (C3cycloalkyl); and wherein R2 is as defined in claim 1. or a salt thereof. 3. A compound of formula (I) according to claim 2, wherein R1 is C1alkyl, C3 cycloalkyl, heterocyclyl, -O-R2, -NH-R2 or -N(R2)2; _ 66 _ wherein each heterocyclyl is selected from the group consisting of azetidinyl, piperidinyl, tetrahydrofuranyl, tetrahydropyranyl and morpholinyl; and wherein each alkyl, cycloalkyl or heterocyclyl group is optionally independently substituted with 1 to 3 F or one substituent selected from the group consisting of CN, OH, CH3, -O-CH3, —C(=O)—CH3 and —C(=O)—cyclopropyl; and wherein R2 is as defined in claim 1. or a salt f. 4. A compound of formula (I) according to any one of claims 1 to 3, wherein R2 is selected from the group consisting of 01alkyl, Cgcycloalkyl, cyclyl, -(C1_2- alkyl)—(Cg_5-cycloalkyl), -alkyl)—heterocyclyl, -(C1_2-alkyl)-aryl, -(C1_2-alkyl)- heteroaryl and -(C1alkyl)-CECH; wherein each cyclyl is a 4- to 6—membered saturated carbocyclic group, in which 1 or 2 CHg-moieties are replaced by a heteroatom ed from NH, O or S; and wherein each aryl is selected from the group consisting of phenyl and naphthyl; and wherein each heteroaryl is a 5- or 6—membered heteroaromatic ring which contains 1, 2 or 3 heteroatoms independently selected from =N-, -NH-, -O- and —S—; and wherein each alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl group is optionally ndently substituted with one or more F, Cl, CN, OH, 01alkyl, -O-(C1alkyl), —(C1alkyl) and —C(=O)—(Cgcycloalkyl). or a salt thereof.

. A compound of formula (I) according to any one of claims 1-3, wherein R2 is selected from the group consisting of: 01alkyl, -CH2—(Cg_4-cycloalkyl), -CH2— heterocyclyl, -CH2—heteroaryl and —CH2—CH2—CECH; wherein each heterocyclyl is selected from the group ting of tetrahydrofuranyl and piperidinyl; and wherein each heteroaryl is selected from the group consisting of isoxazolyl, thiazolyl and thiadiazolyl; and n each alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl group is optionally independently substituted with one or more F, CN, CH3, -OCH3, -C(=O)—CH3 and —C(=O)—cyclopropyl; or a salt thereof. 6. A compound of formula (I) according to any one of claims 1 to 5, wherein A is N; or a salt thereof. 7. A compound of formula (I) according to claim 1, wherein A is N; and R1 is selected from the group ting of cyclopropyl, heterocyclyl and -O-R2; wherein R2 is selected from the group consisting of C1-s-alkyl, -(C1_2-alkyl)-(Cg_ e-cycloalkyl), 2-alkyl)-heteroaryl and —(C1_2-alkyl)-CECH; wherein each heterocyclyl is selected from the group consisting of azetidinyl, piperidinyl, ydrofuranyl, ydropyranyl and morpholinyl; and wherein each heteroaryl is selected from the group ting of isoxazolyl, thiazolyl and thiadiazolyl; and wherein each alkyl, cycloalkyl, heterocyclyl, or heteroaryl group is optionally independently substituted with one or more F, CN, CH3, -OCH3, –C(=O)-CH3 and – C(=O)-cyclopropyl; wherein each of the above-mentioned alkyl groups may be linear or branched and wherein the alkyl groups mentioned in each of the above-mentioned definitions, if not specified otherwise, may be substituted by one or more F; or a salt f. 8. A compound of formula (I) according to claim 1, wherein A is N; R1 is ed from the group consisting of cyclopropyl, heterocyclyl and -O-R2; wherein R2 is selected from the group consisting of C1alkyl, -CH2-(C3cycloalkyl), - CH2-heteroaryl and –CH2-CH2-C≡CH; wherein each heteroaryl is selected from the group consisting of olyl, thiazolyl and thiadiazolyl; and wherein each alkyl, cycloalkyl or heteroaryl group is optionally independently substituted with one or more F, CN and -OCH3. wherein each heterocyclyl is selected from the group ting of azetidinyl, piperidinyl, tetrahydrofuranyl, tetrahydropyranyl and morpholinyl; and wherein each heterocyclyl group is optionally independently substituted with one substituent selected from F, CN, OH, CH3, ; or a salt thereof. 9. A compound of formula (I) according to claim 1 selected from the group consisting of: MN \ / \ N— N— N N F O F H O NH 2 and F N N F O H F N O NH 2 , or a salt thereof.

. The nd of formula (I) according to claim 9 having the structure: N N O H O NH . 11. The compound of formula (I) according to claim 9 having the structure: N N O H O NH HN . 12. The compound of formula (I) according to claim 9 having the structure: F O N N F O H O NH 2 . (24764456_1):SAK 13. The compound of formula (I) according to claim 9 having the structure: N N O H O NH HN . 14. The compound of formula (I) according to claim 9 having the structure: N N F O F H O NH 2 . 15. The compound of formula (I) according to claim 9 having the structure: F N N F O H F N O NH 2 . 16. A pharmaceutically acceptable salt of a compound according to any one of claims 1 to 15. 17. A compound according to any one of claims 1 to 15 or a pharmaceutically acceptable salt thereof for use as a medicament. 18. Use of a compound according to any one of claims 1 to 15 or a pharmaceutically acceptable salt f for the manufacture of a medicament for use in the treatment of NASH lcoholic steatohepatitis), pulmonary fibrosis, chronic obstructive pulmonary disease (COPD), pathy, diabetic retinopathy or pathy. 19. A pharmaceutical composition comprising a compound according to any one of claims 1 to 15 or a pharmaceutically acceptable salt thereof, optionally er with one or more inert carriers and/or diluents. (24764456_1):SAK . Use of a compound according to any one of claims 1 to 15 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating a disease or condition which is mediated by inhibiting the activity of AOC3. 21. A pharmaceutical composition comprising one or more compounds according to one or more of the claims 1 to 15 or a pharmaceutically able salt thereof, and one or more additional therapeutic , optionally together with one or more inert carriers and/or ts. 22. Use of a compound according to any one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for use in the treatment of diabetic retinopathy.

Boehringer eim International GmbH By the Attorneys for the Applicant SPRUSON & FERGUSON Per: (24764456_1):SAK